HRP20040185A2 - 1h-imidazole derivatives having cb<sub>1</sub> agonistic, cb<sub>1</sub> partial agonistic or cb<sub>1</sub> antagonistic activity - Google Patents
1h-imidazole derivatives having cb<sub>1</sub> agonistic, cb<sub>1</sub> partial agonistic or cb<sub>1</sub> antagonistic activity Download PDFInfo
- Publication number
- HRP20040185A2 HRP20040185A2 HR20040185A HRP20040185A HRP20040185A2 HR P20040185 A2 HRP20040185 A2 HR P20040185A2 HR 20040185 A HR20040185 A HR 20040185A HR P20040185 A HRP20040185 A HR P20040185A HR P20040185 A2 HRP20040185 A2 HR P20040185A2
- Authority
- HR
- Croatia
- Prior art keywords
- group
- whose
- groups
- substituted
- imidazole
- Prior art date
Links
- 230000003042 antagnostic effect Effects 0.000 title description 2
- 230000001270 agonistic effect Effects 0.000 title 2
- RAXXELZNTBOGNW-MQIHXRCWSA-N 1h-imidazole Chemical class C1=C[15NH]C=[15N]1 RAXXELZNTBOGNW-MQIHXRCWSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 58
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims description 25
- -1 2-pyridinyl Chemical group 0.000 claims description 21
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- 125000001153 fluoro group Chemical group F* 0.000 claims description 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 17
- 229930003827 cannabinoid Natural products 0.000 claims description 16
- 239000003557 cannabinoid Substances 0.000 claims description 16
- 238000006243 chemical reaction Methods 0.000 claims description 16
- 125000005842 heteroatom Chemical group 0.000 claims description 16
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 15
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 125000001424 substituent group Chemical group 0.000 claims description 15
- 125000000623 heterocyclic group Chemical group 0.000 claims description 14
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 12
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 11
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 11
- 125000005843 halogen group Chemical group 0.000 claims description 11
- 125000002816 methylsulfanyl group Chemical group [H]C([H])([H])S[*] 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 11
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 claims description 11
- 229910052717 sulfur Inorganic materials 0.000 claims description 11
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 claims description 11
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 10
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 7
- 229910052801 chlorine Inorganic materials 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 7
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 claims description 7
- 125000004076 pyridyl group Chemical group 0.000 claims description 7
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 125000003545 alkoxy group Chemical group 0.000 claims description 6
- 125000003118 aryl group Chemical group 0.000 claims description 6
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 6
- 229910052794 bromium Inorganic materials 0.000 claims description 6
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 229920006395 saturated elastomer Polymers 0.000 claims description 6
- 201000010099 disease Diseases 0.000 claims description 5
- 125000001624 naphthyl group Chemical group 0.000 claims description 5
- 125000003373 pyrazinyl group Chemical group 0.000 claims description 5
- 125000002098 pyridazinyl group Chemical group 0.000 claims description 5
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 5
- 125000004306 triazinyl group Chemical group 0.000 claims description 5
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 4
- 125000000081 (C5-C8) cycloalkenyl group Chemical group 0.000 claims description 4
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 125000003277 amino group Chemical group 0.000 claims description 4
- 125000004429 atom Chemical group 0.000 claims description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- 229910052736 halogen Inorganic materials 0.000 claims description 4
- 150000002367 halogens Chemical class 0.000 claims description 4
- 239000001257 hydrogen Substances 0.000 claims description 4
- 229910052739 hydrogen Inorganic materials 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 4
- 230000005062 synaptic transmission Effects 0.000 claims description 4
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 claims description 4
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 208000012902 Nervous system disease Diseases 0.000 claims description 3
- 208000025966 Neurological disease Diseases 0.000 claims description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
- 208000020016 psychiatric disease Diseases 0.000 claims description 3
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 claims description 2
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 208000024827 Alzheimer disease Diseases 0.000 claims description 2
- 208000019901 Anxiety disease Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- 206010008190 Cerebrovascular accident Diseases 0.000 claims description 2
- 206010012289 Dementia Diseases 0.000 claims description 2
- 208000016192 Demyelinating disease Diseases 0.000 claims description 2
- 206010012305 Demyelination Diseases 0.000 claims description 2
- 206010012335 Dependence Diseases 0.000 claims description 2
- 206010012735 Diarrhoea Diseases 0.000 claims description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims description 2
- 208000014094 Dystonic disease Diseases 0.000 claims description 2
- 208000030814 Eating disease Diseases 0.000 claims description 2
- 206010014612 Encephalitis viral Diseases 0.000 claims description 2
- 208000019454 Feeding and Eating disease Diseases 0.000 claims description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 claims description 2
- 208000010412 Glaucoma Diseases 0.000 claims description 2
- 206010019196 Head injury Diseases 0.000 claims description 2
- 208000023105 Huntington disease Diseases 0.000 claims description 2
- 208000026139 Memory disease Diseases 0.000 claims description 2
- 208000007101 Muscle Cramp Diseases 0.000 claims description 2
- 206010028813 Nausea Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 208000018737 Parkinson disease Diseases 0.000 claims description 2
- 208000028017 Psychotic disease Diseases 0.000 claims description 2
- 208000034189 Sclerosis Diseases 0.000 claims description 2
- 208000027520 Somatoform disease Diseases 0.000 claims description 2
- 208000005392 Spasm Diseases 0.000 claims description 2
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 208000000323 Tourette Syndrome Diseases 0.000 claims description 2
- 208000016620 Tourette disease Diseases 0.000 claims description 2
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 2
- 206010044565 Tremor Diseases 0.000 claims description 2
- 206010047700 Vomiting Diseases 0.000 claims description 2
- KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims description 2
- 230000036506 anxiety Effects 0.000 claims description 2
- 208000006673 asthma Diseases 0.000 claims description 2
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 2
- 150000001602 bicycloalkyls Chemical group 0.000 claims description 2
- 201000011510 cancer Diseases 0.000 claims description 2
- 230000002490 cerebral effect Effects 0.000 claims description 2
- 206010008118 cerebral infarction Diseases 0.000 claims description 2
- 208000010877 cognitive disease Diseases 0.000 claims description 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims description 2
- 206010012601 diabetes mellitus Diseases 0.000 claims description 2
- 235000014632 disordered eating Nutrition 0.000 claims description 2
- 206010013663 drug dependence Diseases 0.000 claims description 2
- 208000010118 dystonia Diseases 0.000 claims description 2
- 125000002950 monocyclic group Chemical group 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000008693 nausea Effects 0.000 claims description 2
- 208000004296 neuralgia Diseases 0.000 claims description 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 2
- 208000021722 neuropathic pain Diseases 0.000 claims description 2
- 230000000269 nucleophilic effect Effects 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 208000027753 pain disease Diseases 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 208000020431 spinal cord injury Diseases 0.000 claims description 2
- 239000011593 sulfur Substances 0.000 claims description 2
- 125000001544 thienyl group Chemical group 0.000 claims description 2
- 230000009529 traumatic brain injury Effects 0.000 claims description 2
- 201000002498 viral encephalitis Diseases 0.000 claims description 2
- 230000008673 vomiting Effects 0.000 claims description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 2
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 1
- 125000004800 4-bromophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Br 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 206010040070 Septic Shock Diseases 0.000 claims 1
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims 1
- 210000004556 brain Anatomy 0.000 claims 1
- 125000001309 chloro group Chemical group Cl* 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims 1
- 239000000651 prodrug Substances 0.000 claims 1
- 229940002612 prodrug Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000036303 septic shock Effects 0.000 claims 1
- 208000011117 substance-related disease Diseases 0.000 claims 1
- 238000002844 melting Methods 0.000 description 94
- 230000008018 melting Effects 0.000 description 94
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 46
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 40
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 29
- 239000000203 mixture Substances 0.000 description 29
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
- 239000000243 solution Substances 0.000 description 25
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 22
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 18
- 235000019439 ethyl acetate Nutrition 0.000 description 17
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 16
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 15
- 239000000741 silica gel Substances 0.000 description 15
- 229910002027 silica gel Inorganic materials 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 14
- 102000009132 CB1 Cannabinoid Receptor Human genes 0.000 description 12
- 108010073366 CB1 Cannabinoid Receptor Proteins 0.000 description 11
- 235000017557 sodium bicarbonate Nutrition 0.000 description 11
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 11
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
- 238000004440 column chromatography Methods 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 8
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 8
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 8
- 239000007832 Na2SO4 Substances 0.000 description 7
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 7
- 239000010410 layer Substances 0.000 description 7
- 238000010992 reflux Methods 0.000 description 7
- 229910052938 sodium sulfate Inorganic materials 0.000 description 7
- 235000011152 sodium sulphate Nutrition 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- 238000005160 1H NMR spectroscopy Methods 0.000 description 5
- RAXXELZNTBOGNW-UHFFFAOYSA-N 1H-imidazole Chemical class C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 5
- 229940065144 cannabinoids Drugs 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 239000012044 organic layer Substances 0.000 description 5
- 239000004031 partial agonist Substances 0.000 description 5
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 102000018208 Cannabinoid Receptor Human genes 0.000 description 4
- 108050007331 Cannabinoid receptor Proteins 0.000 description 4
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 description 4
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
- 239000005557 antagonist Substances 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- UZYBCYPTBNXRLH-UHFFFAOYSA-N ethyl 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)imidazole-4-carboxylate Chemical compound N=1C(C(=O)OCC)=CN(C=2C=CC(Cl)=CC=2)C=1C1=CC=C(Cl)C=C1Cl UZYBCYPTBNXRLH-UHFFFAOYSA-N 0.000 description 4
- 229940044551 receptor antagonist Drugs 0.000 description 4
- 239000002464 receptor antagonist Substances 0.000 description 4
- DYWNLSQWJMTVGJ-DKXTVVGFSA-N (1s,2s)-2-amino-1-phenylpropan-1-ol;hydron;chloride Chemical compound Cl.C[C@H](N)[C@@H](O)C1=CC=CC=C1 DYWNLSQWJMTVGJ-DKXTVVGFSA-N 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000004913 activation Effects 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 244000309464 bull Species 0.000 description 3
- 238000010168 coupling process Methods 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 239000003446 ligand Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012299 nitrogen atmosphere Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000003208 petroleum Substances 0.000 description 3
- LWMPFIOTEAXAGV-UHFFFAOYSA-N piperidin-1-amine Chemical compound NN1CCCCC1 LWMPFIOTEAXAGV-UHFFFAOYSA-N 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 239000000018 receptor agonist Substances 0.000 description 3
- 229940044601 receptor agonist Drugs 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- KUGXDNUGDPKZBW-UHFFFAOYSA-N tert-butyl 1-(4-chlorophenyl)-5-cyano-2-(2,4-dichlorophenyl)imidazole-4-carboxylate Chemical compound C=1C=C(Cl)C=CC=1N1C(C#N)=C(C(=O)OC(C)(C)C)N=C1C1=CC=C(Cl)C=C1Cl KUGXDNUGDPKZBW-UHFFFAOYSA-N 0.000 description 3
- OCQYXZPKOQZUNQ-UHFFFAOYSA-N 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)imidazole-4-carboxylic acid Chemical compound N=1C(C(=O)O)=CN(C=2C=CC(Br)=CC=2)C=1C1=CC=C(Cl)C=C1Cl OCQYXZPKOQZUNQ-UHFFFAOYSA-N 0.000 description 2
- FQVFACGJHHJQNN-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)imidazole-4-carboxylic acid Chemical compound N=1C(C(=O)O)=CN(C=2C=CC(Cl)=CC=2)C=1C1=CC=C(Cl)C=C1Cl FQVFACGJHHJQNN-UHFFFAOYSA-N 0.000 description 2
- TXTLOBKZXYXVBX-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-cyano-2-(2,4-dichlorophenyl)imidazole-4-carboxylic acid Chemical compound C=1C=C(Cl)C=CC=1N1C(C#N)=C(C(=O)O)N=C1C1=CC=C(Cl)C=C1Cl TXTLOBKZXYXVBX-UHFFFAOYSA-N 0.000 description 2
- QQIRTFPHUHBRRB-UHFFFAOYSA-N 2,4-dichloro-n'-(4-chlorophenyl)benzenecarboximidamide Chemical compound C1=CC(Cl)=CC=C1NC(=N)C1=CC=C(Cl)C=C1Cl QQIRTFPHUHBRRB-UHFFFAOYSA-N 0.000 description 2
- GACNIJHLDRRTOL-UHFFFAOYSA-N 2,4-dichloro-n'-[4-(trifluoromethyl)phenyl]benzenecarboximidamide Chemical compound C1=CC(C(F)(F)F)=CC=C1NC(=N)C1=CC=C(Cl)C=C1Cl GACNIJHLDRRTOL-UHFFFAOYSA-N 0.000 description 2
- CKHKFNQLWIROHE-UHFFFAOYSA-N 2,4-dichloro-n-[4-(trifluoromethyl)phenyl]benzamide Chemical compound C1=CC(C(F)(F)F)=CC=C1NC(=O)C1=CC=C(Cl)C=C1Cl CKHKFNQLWIROHE-UHFFFAOYSA-N 0.000 description 2
- KQCMTOWTPBNWDB-UHFFFAOYSA-N 2,4-dichloroaniline Chemical compound NC1=CC=C(Cl)C=C1Cl KQCMTOWTPBNWDB-UHFFFAOYSA-N 0.000 description 2
- SNXHEKLUMHMSNN-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-5-methylimidazole-4-carboxylic acid Chemical compound C1=CC(OC)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(O)=O)=C1C SNXHEKLUMHMSNN-UHFFFAOYSA-N 0.000 description 2
- QHQZFBXRRMRFSQ-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-5-methylimidazole-4-carbonyl chloride Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(C)=C(C(Cl)=O)N=C1C1=CC=C(Cl)C=C1 QHQZFBXRRMRFSQ-UHFFFAOYSA-N 0.000 description 2
- GJNGXPDXRVXSEH-UHFFFAOYSA-N 4-chlorobenzonitrile Chemical compound ClC1=CC=C(C#N)C=C1 GJNGXPDXRVXSEH-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 101710187010 Cannabinoid receptor 1 Proteins 0.000 description 2
- 102100033868 Cannabinoid receptor 1 Human genes 0.000 description 2
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000003375 cannabimimetic effect Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 description 2
- 150000003983 crown ethers Chemical class 0.000 description 2
- 239000002739 cryptand Substances 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- WNNIGAWMMGEJKM-UHFFFAOYSA-N ethyl 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)imidazole-4-carboxylate Chemical compound N=1C(C(=O)OCC)=CN(C=2C=CC(Br)=CC=2)C=1C1=CC=C(Cl)C=C1Cl WNNIGAWMMGEJKM-UHFFFAOYSA-N 0.000 description 2
- ZRUUNAARBYPXJU-UHFFFAOYSA-N ethyl 1-(4-bromophenyl)-5-chloro-2-(2,4-dichlorophenyl)imidazole-4-carboxylate Chemical compound C=1C=C(Br)C=CC=1N1C(Cl)=C(C(=O)OCC)N=C1C1=CC=C(Cl)C=C1Cl ZRUUNAARBYPXJU-UHFFFAOYSA-N 0.000 description 2
- HZQIKMFUCARKQP-UHFFFAOYSA-N ethyl 2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-5-methylimidazole-4-carboxylate Chemical compound C=1C=C(OC)C=CC=1N1C(C)=C(C(=O)OCC)N=C1C1=CC=C(Cl)C=C1Cl HZQIKMFUCARKQP-UHFFFAOYSA-N 0.000 description 2
- CXGJBCMYPMUFSU-UHFFFAOYSA-N ethyl 2-(2,4-dichlorophenyl)-5-methyl-1-[4-(trifluoromethyl)phenyl]imidazole-4-carboxylate Chemical compound C=1C=C(C(F)(F)F)C=CC=1N1C(C)=C(C(=O)OCC)N=C1C1=CC=C(Cl)C=C1Cl CXGJBCMYPMUFSU-UHFFFAOYSA-N 0.000 description 2
- JMQXRRBDPSPHKV-UHFFFAOYSA-N ethyl 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-5-methylimidazole-4-carboxylate Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(C)=C(C(=O)OCC)N=C1C1=CC=C(Cl)C=C1 JMQXRRBDPSPHKV-UHFFFAOYSA-N 0.000 description 2
- SIOIQIWIQSMQAG-UHFFFAOYSA-N ethyl 3-bromo-2-oxobutanoate Chemical compound CCOC(=O)C(=O)C(C)Br SIOIQIWIQSMQAG-UHFFFAOYSA-N 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 2
- 235000019341 magnesium sulphate Nutrition 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- KQLIBRYGIIAMAM-UHFFFAOYSA-N tert-butyl 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)imidazole-4-carboxylate Chemical compound N=1C(C(=O)OC(C)(C)C)=CN(C=2C=CC(Cl)=CC=2)C=1C1=CC=C(Cl)C=C1Cl KQLIBRYGIIAMAM-UHFFFAOYSA-N 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- JONIMGVUGJVFQD-UHFFFAOYSA-N (4-methylphenyl)sulfonylformonitrile Chemical compound CC1=CC=C(S(=O)(=O)C#N)C=C1 JONIMGVUGJVFQD-UHFFFAOYSA-N 0.000 description 1
- NLMDJJTUQPXZFG-UHFFFAOYSA-N 1,4,10,13-tetraoxa-7,16-diazacyclooctadecane Chemical compound C1COCCOCCNCCOCCOCCN1 NLMDJJTUQPXZFG-UHFFFAOYSA-N 0.000 description 1
- TZEUEXZROXFIIO-UHFFFAOYSA-N 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-n-[(2-methylpropan-2-yl)oxy]imidazole-4-carboxamide Chemical compound C=1C=C(Br)C=CC=1N1C(CC)=C(C(=O)NOC(C)(C)C)N=C1C1=CC=C(Cl)C=C1Cl TZEUEXZROXFIIO-UHFFFAOYSA-N 0.000 description 1
- VNSIAYZGNJDGOE-UHFFFAOYSA-N 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-n-pentylimidazole-4-carboxamide Chemical compound C=1C=C(Br)C=CC=1N1C(CC)=C(C(=O)NCCCCC)N=C1C1=CC=C(Cl)C=C1Cl VNSIAYZGNJDGOE-UHFFFAOYSA-N 0.000 description 1
- AFBXAMDVJUKHMK-UHFFFAOYSA-N 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C=1C=C(Br)C=CC=1N1C(CC)=C(C(=O)NN2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl AFBXAMDVJUKHMK-UHFFFAOYSA-N 0.000 description 1
- XTZUEDAKHUNVEK-UHFFFAOYSA-N 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-methyl-n-[(2-methylpropan-2-yl)oxy]imidazole-4-carboxamide Chemical compound C=1C=C(Br)C=CC=1N1C(C)=C(C(=O)NOC(C)(C)C)N=C1C1=CC=C(Cl)C=C1Cl XTZUEDAKHUNVEK-UHFFFAOYSA-N 0.000 description 1
- PLTSATGWXQRBDE-UHFFFAOYSA-N 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-5-methyl-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C=1C=C(Br)C=CC=1N1C(C)=C(C(=O)NN2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl PLTSATGWXQRBDE-UHFFFAOYSA-N 0.000 description 1
- YCZSEPKOSIJWCU-UHFFFAOYSA-N 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-n-[(2-methylpropan-2-yl)oxy]imidazole-4-carboxamide Chemical compound N=1C(C(=O)NOC(C)(C)C)=CN(C=2C=CC(Br)=CC=2)C=1C1=CC=C(Cl)C=C1Cl YCZSEPKOSIJWCU-UHFFFAOYSA-N 0.000 description 1
- GCQWDIQUVRTULL-UHFFFAOYSA-N 1-(4-bromophenyl)-2-(2,4-dichlorophenyl)-n-pyrrolidin-1-ylimidazole-4-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1C1=NC(C(=O)NN2CCCC2)=CN1C1=CC=C(Br)C=C1 GCQWDIQUVRTULL-UHFFFAOYSA-N 0.000 description 1
- SHLMKTXWDGEQRU-UHFFFAOYSA-N 1-(4-bromophenyl)-5-chloro-2-(2,4-dichlorophenyl)-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C=1C=C(Br)C=CC=1N1C(Cl)=C(C(=O)NN2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl SHLMKTXWDGEQRU-UHFFFAOYSA-N 0.000 description 1
- XWUCVTHIHTTWIK-UHFFFAOYSA-N 1-(4-bromophenyl)-n-cyclohexyl-2-(2,4-dichlorophenyl)-5-ethylimidazole-4-carboxamide Chemical compound C=1C=C(Br)C=CC=1N1C(CC)=C(C(=O)NC2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl XWUCVTHIHTTWIK-UHFFFAOYSA-N 0.000 description 1
- LJYKHPSJOACCMJ-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(1,5-dimethylpyrrol-2-yl)-5-methyl-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound CN1C(C)=CC=C1C1=NC(C(=O)NN2CCCCC2)=C(C)N1C1=CC=C(Cl)C=C1 LJYKHPSJOACCMJ-UHFFFAOYSA-N 0.000 description 1
- UXXRGXFIRDLVIT-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-n-[(2-methylpropan-2-yl)oxy]imidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(CC)=C(C(=O)NOC(C)(C)C)N=C1C1=CC=C(Cl)C=C1Cl UXXRGXFIRDLVIT-UHFFFAOYSA-N 0.000 description 1
- RQFDHAZJXWQQBK-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-ethyl-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(CC)=C(C(=O)NN2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl RQFDHAZJXWQQBK-UHFFFAOYSA-N 0.000 description 1
- MCLDRTREOJASMB-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-iodo-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NN2CCCCC2)=C1I MCLDRTREOJASMB-UHFFFAOYSA-N 0.000 description 1
- LECJJHPDXALPIK-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-n-(oxan-2-yloxy)imidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NOC2OCCCC2)N=C1C1=CC=C(Cl)C=C1Cl LECJJHPDXALPIK-UHFFFAOYSA-N 0.000 description 1
- PNYCYGVLNOKFSQ-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-n-[(2-methylpropan-2-yl)oxy]imidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NOC(C)(C)C)N=C1C1=CC=C(Cl)C=C1Cl PNYCYGVLNOKFSQ-UHFFFAOYSA-N 0.000 description 1
- GJJWPAHIGGXADY-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-n-morpholin-4-ylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NN2CCOCC2)N=C1C1=CC=C(Cl)C=C1Cl GJJWPAHIGGXADY-UHFFFAOYSA-N 0.000 description 1
- GGRYXYYKYMJWIV-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-n-pentylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NCCCCC)N=C1C1=CC=C(Cl)C=C1Cl GGRYXYYKYMJWIV-UHFFFAOYSA-N 0.000 description 1
- QPHDCJUYVKUJRA-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-n-phenylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NC=2C=CC=CC=2)N=C1C1=CC=C(Cl)C=C1Cl QPHDCJUYVKUJRA-UHFFFAOYSA-N 0.000 description 1
- KKEBVIMUGTZZBL-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NN2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl KKEBVIMUGTZZBL-UHFFFAOYSA-N 0.000 description 1
- OGHUHFAJQSONNN-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methyl-n-pyrrolidin-1-ylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NN2CCCC2)N=C1C1=CC=C(Cl)C=C1Cl OGHUHFAJQSONNN-UHFFFAOYSA-N 0.000 description 1
- XBQPLQNMIBRBCV-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-n,n-diethylimidazole-4-carboxamide Chemical compound N=1C(C(=O)N(CC)CC)=CN(C=2C=CC(Cl)=CC=2)C=1C1=CC=C(Cl)C=C1Cl XBQPLQNMIBRBCV-UHFFFAOYSA-N 0.000 description 1
- HTRCGPITLYPGLB-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-n-(2-fluoroethyl)-5-methylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NCCF)N=C1C1=CC=C(Cl)C=C1Cl HTRCGPITLYPGLB-UHFFFAOYSA-N 0.000 description 1
- RHWRJKGGXVYGPD-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-n-[(2-methylpropan-2-yl)oxy]imidazole-4-carboxamide Chemical compound N=1C(C(=O)NOC(C)(C)C)=CN(C=2C=CC(Cl)=CC=2)C=1C1=CC=C(Cl)C=C1Cl RHWRJKGGXVYGPD-UHFFFAOYSA-N 0.000 description 1
- RGDWYZVJKQZPCR-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-n-[(4-fluorophenyl)methyl]-5-methylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NCC=2C=CC(F)=CC=2)N=C1C1=CC=C(Cl)C=C1Cl RGDWYZVJKQZPCR-UHFFFAOYSA-N 0.000 description 1
- DKSATWBFRZWIOX-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-n-[(4-fluorophenyl)methyl]imidazole-4-carboxamide Chemical compound C1=CC(F)=CC=C1CNC(=O)C1=CN(C=2C=CC(Cl)=CC=2)C(C=2C(=CC(Cl)=CC=2)Cl)=N1 DKSATWBFRZWIOX-UHFFFAOYSA-N 0.000 description 1
- MYSGZZOTCIEIBN-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-n-phenylimidazole-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NC=2C=CC=CC=2)=C1 MYSGZZOTCIEIBN-UHFFFAOYSA-N 0.000 description 1
- CPZFFCWPBSKKAF-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NN2CCCCC2)=C1 CPZFFCWPBSKKAF-UHFFFAOYSA-N 0.000 description 1
- MAUBLDPPCZITOG-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-n-pyrrolidin-1-ylimidazole-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NN2CCCC2)=C1 MAUBLDPPCZITOG-UHFFFAOYSA-N 0.000 description 1
- HIEMKJSSXPDXSO-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)imidazole-4-carbonyl chloride Chemical compound N=1C(C(=O)Cl)=CN(C=2C=CC(Cl)=CC=2)C=1C1=CC=C(Cl)C=C1Cl HIEMKJSSXPDXSO-UHFFFAOYSA-N 0.000 description 1
- LOYBJSXDJRFXGA-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-chloro-2-(trifluoromethyl)phenyl]-5-methyl-n-pentylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NCCCCC)N=C1C1=CC=C(Cl)C=C1C(F)(F)F LOYBJSXDJRFXGA-UHFFFAOYSA-N 0.000 description 1
- KBSISTGQJOICMP-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-chloro-2-(trifluoromethyl)phenyl]-5-methyl-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NN2CCCCC2)N=C1C1=CC=C(Cl)C=C1C(F)(F)F KBSISTGQJOICMP-UHFFFAOYSA-N 0.000 description 1
- BSOQXJWSLLCWAT-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-chloro-2-(trifluoromethyl)phenyl]-n-(2,2,2-trifluoroethyl)imidazole-4-carboxamide Chemical compound N=1C(C(=O)NCC(F)(F)F)=CN(C=2C=CC(Cl)=CC=2)C=1C1=CC=C(Cl)C=C1C(F)(F)F BSOQXJWSLLCWAT-UHFFFAOYSA-N 0.000 description 1
- YQAPRDAMNGCMED-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-chloro-2-(trifluoromethyl)phenyl]-n-cyclohexyl-5-methylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NC2CCCCC2)N=C1C1=CC=C(Cl)C=C1C(F)(F)F YQAPRDAMNGCMED-UHFFFAOYSA-N 0.000 description 1
- WWFMEJFZCAXZPY-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-chloro-2-(trifluoromethyl)phenyl]-n-cyclohexylimidazole-4-carboxamide Chemical compound FC(F)(F)C1=CC(Cl)=CC=C1C1=NC(C(=O)NC2CCCCC2)=CN1C1=CC=C(Cl)C=C1 WWFMEJFZCAXZPY-UHFFFAOYSA-N 0.000 description 1
- CQDOGEXMJOZWAE-UHFFFAOYSA-N 1-(4-chlorophenyl)-2-[4-chloro-2-(trifluoromethyl)phenyl]-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound FC(F)(F)C1=CC(Cl)=CC=C1C1=NC(C(=O)NN2CCCCC2)=CN1C1=CC=C(Cl)C=C1 CQDOGEXMJOZWAE-UHFFFAOYSA-N 0.000 description 1
- XIRHISFCEKCBJD-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-cyano-2-(2,4-dichlorophenyl)-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C#N)=C(C(=O)NN2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl XIRHISFCEKCBJD-UHFFFAOYSA-N 0.000 description 1
- OKDOSEGZYWGKMW-UHFFFAOYSA-N 1-(4-chlorophenyl)-5-cyano-n-cyclohexyl-2-(2,4-dichlorophenyl)imidazole-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C#N)=C(C(=O)NC2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl OKDOSEGZYWGKMW-UHFFFAOYSA-N 0.000 description 1
- UYDJPLQCNWEWBD-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-cyclohexyl-2-(1,5-dimethylpyrrol-2-yl)-5-methylimidazole-4-carboxamide Chemical compound CN1C(C)=CC=C1C1=NC(C(=O)NC2CCCCC2)=C(C)N1C1=CC=C(Cl)C=C1 UYDJPLQCNWEWBD-UHFFFAOYSA-N 0.000 description 1
- DOCHZHSBYZUORF-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-cyclohexyl-2-(2,4-dichlorophenyl)-5-iodoimidazole-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NC2CCCCC2)=C1I DOCHZHSBYZUORF-UHFFFAOYSA-N 0.000 description 1
- YCVHHBIJYZETRR-UHFFFAOYSA-N 1-(4-chlorophenyl)-n-cyclohexyl-2-(2,4-dichlorophenyl)imidazole-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NC2CCCCC2)=C1 YCVHHBIJYZETRR-UHFFFAOYSA-N 0.000 description 1
- UDNOQKDUBDNUIZ-UHFFFAOYSA-N 1-(4-chloropyridin-2-yl)-2-(2,4-dichlorophenyl)-5-ethyl-n-[(4-fluorophenyl)methyl]imidazole-4-carboxamide Chemical compound C=1C(Cl)=CC=NC=1N1C(CC)=C(C(=O)NCC=2C=CC(F)=CC=2)N=C1C1=CC=C(Cl)C=C1Cl UDNOQKDUBDNUIZ-UHFFFAOYSA-N 0.000 description 1
- ZDTZDVGEOOVXTH-UHFFFAOYSA-N 1-(4-chloropyridin-2-yl)-2-(2,4-dichlorophenyl)-5-ethyl-n-morpholin-4-ylimidazole-4-carboxamide Chemical compound C=1C(Cl)=CC=NC=1N1C(CC)=C(C(=O)NN2CCOCC2)N=C1C1=CC=C(Cl)C=C1Cl ZDTZDVGEOOVXTH-UHFFFAOYSA-N 0.000 description 1
- FRVBQUOHEOBURA-UHFFFAOYSA-N 1-(4-chloropyridin-2-yl)-2-(2,4-dichlorophenyl)-5-ethyl-n-pentylimidazole-4-carboxamide Chemical compound C=1C(Cl)=CC=NC=1N1C(CC)=C(C(=O)NCCCCC)N=C1C1=CC=C(Cl)C=C1Cl FRVBQUOHEOBURA-UHFFFAOYSA-N 0.000 description 1
- VXNVNNMYAHHVCN-UHFFFAOYSA-N 1-(4-chloropyridin-2-yl)-2-(2,4-dichlorophenyl)-5-ethyl-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C=1C(Cl)=CC=NC=1N1C(CC)=C(C(=O)NN2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl VXNVNNMYAHHVCN-UHFFFAOYSA-N 0.000 description 1
- DUJBTKLEZZOSNY-UHFFFAOYSA-N 1-(4-chloropyridin-2-yl)-2-(2,4-dichlorophenyl)-5-methyl-n-morpholin-4-ylimidazole-4-carboxamide Chemical compound C=1C(Cl)=CC=NC=1N1C(C)=C(C(=O)NN2CCOCC2)N=C1C1=CC=C(Cl)C=C1Cl DUJBTKLEZZOSNY-UHFFFAOYSA-N 0.000 description 1
- NHPFFTWZTVFBMZ-UHFFFAOYSA-N 1-(4-chloropyridin-2-yl)-2-(2,4-dichlorophenyl)-5-methyl-n-pentylimidazole-4-carboxamide Chemical compound C=1C(Cl)=CC=NC=1N1C(C)=C(C(=O)NCCCCC)N=C1C1=CC=C(Cl)C=C1Cl NHPFFTWZTVFBMZ-UHFFFAOYSA-N 0.000 description 1
- QGQXUYUPKOKDNE-UHFFFAOYSA-N 1-(4-chloropyridin-2-yl)-2-(2,4-dichlorophenyl)-5-methyl-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C=1C(Cl)=CC=NC=1N1C(C)=C(C(=O)NN2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl QGQXUYUPKOKDNE-UHFFFAOYSA-N 0.000 description 1
- ZCSRAGFSWYIFHI-UHFFFAOYSA-N 1-(4-chloropyridin-2-yl)-2-(2,4-dichlorophenyl)-n-[(4-fluorophenyl)methyl]-5-methylimidazole-4-carboxamide Chemical compound C=1C(Cl)=CC=NC=1N1C(C)=C(C(=O)NCC=2C=CC(F)=CC=2)N=C1C1=CC=C(Cl)C=C1Cl ZCSRAGFSWYIFHI-UHFFFAOYSA-N 0.000 description 1
- FETBGDMTRFHVPE-UHFFFAOYSA-N 1-(4-chloropyridin-2-yl)-n-cyclohexyl-2-(2,4-dichlorophenyl)-5-ethylimidazole-4-carboxamide Chemical compound C=1C(Cl)=CC=NC=1N1C(CC)=C(C(=O)NC2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl FETBGDMTRFHVPE-UHFFFAOYSA-N 0.000 description 1
- UBMWLNKLJXXNBQ-UHFFFAOYSA-N 1-(4-chloropyridin-2-yl)-n-cyclohexyl-2-(2,4-dichlorophenyl)-5-methylimidazole-4-carboxamide Chemical compound C=1C(Cl)=CC=NC=1N1C(C)=C(C(=O)NC2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl UBMWLNKLJXXNBQ-UHFFFAOYSA-N 0.000 description 1
- NOUDGPISLXECAJ-UHFFFAOYSA-N 1h-imidazole-5-carbonyl chloride Chemical compound ClC(=O)C1=CNC=N1 NOUDGPISLXECAJ-UHFFFAOYSA-N 0.000 description 1
- HZUGXKOBWNOCKU-UHFFFAOYSA-N 2,4-dichloro-n'-(4-methoxyphenyl)benzenecarboximidamide Chemical compound C1=CC(OC)=CC=C1NC(=N)C1=CC=C(Cl)C=C1Cl HZUGXKOBWNOCKU-UHFFFAOYSA-N 0.000 description 1
- GRUHREVRSOOQJG-UHFFFAOYSA-N 2,4-dichlorobenzonitrile Chemical compound ClC1=CC=C(C#N)C(Cl)=C1 GRUHREVRSOOQJG-UHFFFAOYSA-N 0.000 description 1
- CEOCVKWBUWKBKA-UHFFFAOYSA-N 2,4-dichlorobenzoyl chloride Chemical compound ClC(=O)C1=CC=C(Cl)C=C1Cl CEOCVKWBUWKBKA-UHFFFAOYSA-N 0.000 description 1
- PIQKCFMGYGBVIK-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-5-methyl-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C=1C=C(F)C=CC=1N1C(C)=C(C(=O)NN2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl PIQKCFMGYGBVIK-UHFFFAOYSA-N 0.000 description 1
- HZDHNBOYRXSVQJ-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C1=CC(F)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NN2CCCCC2)=C1 HZDHNBOYRXSVQJ-UHFFFAOYSA-N 0.000 description 1
- VZVKCHVLMNXLHW-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-5-methyl-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NN2CCCCC2)=C1C VZVKCHVLMNXLHW-UHFFFAOYSA-N 0.000 description 1
- MIHNLYOTRRTNFJ-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NN2CCCCC2)=C1 MIHNLYOTRRTNFJ-UHFFFAOYSA-N 0.000 description 1
- XJQDCMMEDVRVBS-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)-5-methyl-1-[4-(trifluoromethyl)phenyl]imidazole-4-carboxylic acid Chemical compound C=1C=C(C(F)(F)F)C=CC=1N1C(C)=C(C(O)=O)N=C1C1=CC=C(Cl)C=C1Cl XJQDCMMEDVRVBS-UHFFFAOYSA-N 0.000 description 1
- LXHJQKRDYPVDAL-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)-5-methyl-n-piperidin-1-yl-1-[4-(trifluoromethyl)phenyl]imidazole-4-carboxamide Chemical compound C=1C=C(C(F)(F)F)C=CC=1N1C(C)=C(C(=O)NN2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl LXHJQKRDYPVDAL-UHFFFAOYSA-N 0.000 description 1
- KHBUUJAPLBLUGB-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)-n-pentyl-1-pyridin-3-ylimidazole-4-carboxamide Chemical compound N=1C(C(=O)NCCCCC)=CN(C=2C=NC=CC=2)C=1C1=CC=C(Cl)C=C1Cl KHBUUJAPLBLUGB-UHFFFAOYSA-N 0.000 description 1
- ZZPDODRCDPPYKC-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)-n-piperidin-1-yl-1-[4-(trifluoromethyl)phenyl]imidazole-4-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NN2CCCCC2)=C1 ZZPDODRCDPPYKC-UHFFFAOYSA-N 0.000 description 1
- WNJDNWXZMKFRJK-UHFFFAOYSA-N 2-(2,4-dichlorophenyl)-n-piperidin-1-yl-1-pyridin-3-ylimidazole-4-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1C1=NC(C(=O)NN2CCCCC2)=CN1C1=CC=CN=C1 WNJDNWXZMKFRJK-UHFFFAOYSA-N 0.000 description 1
- RJMNZCAGYIQAGQ-UHFFFAOYSA-N 2-(2,5-dichlorophenyl)-5-ethyl-1-phenyl-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C=1C=CC=CC=1N1C(CC)=C(C(=O)NN2CCCCC2)N=C1C1=CC(Cl)=CC=C1Cl RJMNZCAGYIQAGQ-UHFFFAOYSA-N 0.000 description 1
- WUJTXJXXRUZZPV-UHFFFAOYSA-N 2-(2,5-dichlorophenyl)-5-methyl-1-phenyl-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C=1C=CC=CC=1N1C(C)=C(C(=O)NN2CCCCC2)N=C1C1=CC(Cl)=CC=C1Cl WUJTXJXXRUZZPV-UHFFFAOYSA-N 0.000 description 1
- AJBLNNZIKFJBGJ-UHFFFAOYSA-N 2-(2-chlorophenyl)-1-(3-fluorophenyl)-5-methyl-n-pentylimidazole-4-carboxamide Chemical compound C=1C=CC(F)=CC=1N1C(C)=C(C(=O)NCCCCC)N=C1C1=CC=CC=C1Cl AJBLNNZIKFJBGJ-UHFFFAOYSA-N 0.000 description 1
- AOCHSHKWGVRFEO-UHFFFAOYSA-N 2-(2-chlorophenyl)-1-(3-fluorophenyl)-5-methyl-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C=1C=CC(F)=CC=1N1C(C)=C(C(=O)NN2CCCCC2)N=C1C1=CC=CC=C1Cl AOCHSHKWGVRFEO-UHFFFAOYSA-N 0.000 description 1
- ZLEZEXVOMLFEJQ-UHFFFAOYSA-N 2-(2-chlorophenyl)-1-(3-fluorophenyl)-n-[2-(4-fluorophenyl)ethyl]-5-methylimidazole-4-carboxamide Chemical compound C=1C=CC(F)=CC=1N1C(C)=C(C(=O)NCCC=2C=CC(F)=CC=2)N=C1C1=CC=CC=C1Cl ZLEZEXVOMLFEJQ-UHFFFAOYSA-N 0.000 description 1
- SPDFXOWMDJEXAR-UHFFFAOYSA-N 2-(2-chlorophenyl)-n-cyclohexyl-1-(3-fluorophenyl)-5-methylimidazole-4-carboxamide Chemical compound C=1C=CC(F)=CC=1N1C(C)=C(C(=O)NC2CCCCC2)N=C1C1=CC=CC=C1Cl SPDFXOWMDJEXAR-UHFFFAOYSA-N 0.000 description 1
- DCMOKKLQDPGGHS-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenyl)-1-(4-chlorophenyl)-5-methyl-n-pentylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NCCCCC)N=C1C1=CC=C(Cl)C=C1F DCMOKKLQDPGGHS-UHFFFAOYSA-N 0.000 description 1
- DUXPSBPTHURSBA-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenyl)-1-(4-chlorophenyl)-5-methyl-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NN2CCCCC2)N=C1C1=CC=C(Cl)C=C1F DUXPSBPTHURSBA-UHFFFAOYSA-N 0.000 description 1
- HAZKVWRKKUQVSH-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenyl)-1-(4-chlorophenyl)-n-cyclohexyl-5-methylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NC2CCCCC2)N=C1C1=CC=C(Cl)C=C1F HAZKVWRKKUQVSH-UHFFFAOYSA-N 0.000 description 1
- JDEOVZDYIHGPOO-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenyl)-1-(4-chlorophenyl)-n-cyclohexylimidazole-4-carboxamide Chemical compound FC1=CC(Cl)=CC=C1C1=NC(C(=O)NC2CCCCC2)=CN1C1=CC=C(Cl)C=C1 JDEOVZDYIHGPOO-UHFFFAOYSA-N 0.000 description 1
- JFSXLPIMYXNSMQ-UHFFFAOYSA-N 2-(4-chloro-2-fluorophenyl)-1-(4-chlorophenyl)-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound FC1=CC(Cl)=CC=C1C1=NC(C(=O)NN2CCCCC2)=CN1C1=CC=C(Cl)C=C1 JFSXLPIMYXNSMQ-UHFFFAOYSA-N 0.000 description 1
- XWKPZKFXLHZNQX-UHFFFAOYSA-N 2-(4-chloro-2-methoxyphenyl)-1-(4-chlorophenyl)-5-methyl-n-pentylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NCCCCC)N=C1C1=CC=C(Cl)C=C1OC XWKPZKFXLHZNQX-UHFFFAOYSA-N 0.000 description 1
- LVCXSRWNHMLVCP-UHFFFAOYSA-N 2-(4-chloro-2-methoxyphenyl)-1-(4-chlorophenyl)-5-methyl-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound COC1=CC(Cl)=CC=C1C1=NC(C(=O)NN2CCCCC2)=C(C)N1C1=CC=C(Cl)C=C1 LVCXSRWNHMLVCP-UHFFFAOYSA-N 0.000 description 1
- WBNNOAZNGYXUBK-UHFFFAOYSA-N 2-(4-chloro-2-methoxyphenyl)-1-(4-chlorophenyl)-n-cyclohexyl-5-methylimidazole-4-carboxamide Chemical compound COC1=CC(Cl)=CC=C1C1=NC(C(=O)NC2CCCCC2)=C(C)N1C1=CC=C(Cl)C=C1 WBNNOAZNGYXUBK-UHFFFAOYSA-N 0.000 description 1
- VZWSQUIVWPZHIX-UHFFFAOYSA-N 2-(4-chloro-2-methoxyphenyl)-1-(4-chlorophenyl)-n-cyclohexylimidazole-4-carboxamide Chemical compound COC1=CC(Cl)=CC=C1C1=NC(C(=O)NC2CCCCC2)=CN1C1=CC=C(Cl)C=C1 VZWSQUIVWPZHIX-UHFFFAOYSA-N 0.000 description 1
- YVZPKZRRXGGHGN-UHFFFAOYSA-N 2-(4-chloro-2-methoxyphenyl)-1-(4-chlorophenyl)-n-pentylimidazole-4-carboxamide Chemical compound N=1C(C(=O)NCCCCC)=CN(C=2C=CC(Cl)=CC=2)C=1C1=CC=C(Cl)C=C1OC YVZPKZRRXGGHGN-UHFFFAOYSA-N 0.000 description 1
- NQZVEBSGPMWCFR-UHFFFAOYSA-N 2-(4-chloro-2-methoxyphenyl)-1-(4-chlorophenyl)-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound COC1=CC(Cl)=CC=C1C1=NC(C(=O)NN2CCCCC2)=CN1C1=CC=C(Cl)C=C1 NQZVEBSGPMWCFR-UHFFFAOYSA-N 0.000 description 1
- NNCYNUUMISWPFX-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-5-methyl-n-[(2-methylpropan-2-yl)oxy]imidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(C)=C(C(=O)NOC(C)(C)C)N=C1C1=CC=C(Cl)C=C1 NNCYNUUMISWPFX-UHFFFAOYSA-N 0.000 description 1
- DMTUNYPKQZNKIZ-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-5-methylimidazole-4-carboxylic acid Chemical compound C=1C=C(Cl)C=C(Cl)C=1N1C(C)=C(C(O)=O)N=C1C1=CC=C(Cl)C=C1 DMTUNYPKQZNKIZ-UHFFFAOYSA-N 0.000 description 1
- XZUKDNRETJUNGW-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-n-[(2-methylpropan-2-yl)oxy]imidazole-4-carboxamide Chemical compound N=1C(C(=O)NOC(C)(C)C)=CN(C=2C(=CC(Cl)=CC=2)Cl)C=1C1=CC=C(Cl)C=C1 XZUKDNRETJUNGW-UHFFFAOYSA-N 0.000 description 1
- BSROPESOPXQHJD-UHFFFAOYSA-N 2-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-n-piperidin-1-ylimidazole-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1C1=NC(C(=O)NN2CCCCC2)=CN1C1=CC=C(Cl)C=C1Cl BSROPESOPXQHJD-UHFFFAOYSA-N 0.000 description 1
- QSNSCYSYFYORTR-UHFFFAOYSA-N 4-chloroaniline Chemical compound NC1=CC=C(Cl)C=C1 QSNSCYSYFYORTR-UHFFFAOYSA-N 0.000 description 1
- ODGIMMLDVSWADK-UHFFFAOYSA-N 4-trifluoromethylaniline Chemical compound NC1=CC=C(C(F)(F)F)C=C1 ODGIMMLDVSWADK-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- 241000722948 Apocynum cannabinum Species 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 229940124802 CB1 antagonist Drugs 0.000 description 1
- 229940123158 Cannabinoid CB1 receptor antagonist Drugs 0.000 description 1
- 229940122820 Cannabinoid receptor antagonist Drugs 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 235000008697 Cannabis sativa Nutrition 0.000 description 1
- 241000699802 Cricetulus griseus Species 0.000 description 1
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 235000015928 Hibiscus cannabinus Nutrition 0.000 description 1
- 101000710899 Homo sapiens Cannabinoid receptor 1 Proteins 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 1
- YGYAWVDWMABLBF-UHFFFAOYSA-N Phosgene Chemical compound ClC(Cl)=O YGYAWVDWMABLBF-UHFFFAOYSA-N 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- 229910006024 SO2Cl2 Inorganic materials 0.000 description 1
- 229910006124 SOCl2 Inorganic materials 0.000 description 1
- CYQFCXCEBYINGO-UHFFFAOYSA-N THC Natural products C1=C(C)CCC2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3C21 CYQFCXCEBYINGO-UHFFFAOYSA-N 0.000 description 1
- IVOMOUWHDPKRLL-UHFFFAOYSA-N UNPD107823 Natural products O1C2COP(O)(=O)OC2C(O)C1N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-UHFFFAOYSA-N 0.000 description 1
- RUAYKRGXLHCWBI-UHFFFAOYSA-N [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methylimidazol-4-yl]-(1,2,3,4-tetrahydroisoquinolin-1-yl)methanone Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)C2C3=CC=CC=C3CCN2)N=C1C1=CC=C(Cl)C=C1Cl RUAYKRGXLHCWBI-UHFFFAOYSA-N 0.000 description 1
- JHZQLCVGUFCRSM-UHFFFAOYSA-N [1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methylimidazol-4-yl]-(4-hydroxypiperidin-1-yl)methanone Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)N2CCC(O)CC2)N=C1C1=CC=C(Cl)C=C1Cl JHZQLCVGUFCRSM-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 238000007112 amidation reaction Methods 0.000 description 1
- LGEQQWMQCRIYKG-DOFZRALJSA-N anandamide Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(=O)NCCO LGEQQWMQCRIYKG-DOFZRALJSA-N 0.000 description 1
- LGEQQWMQCRIYKG-UHFFFAOYSA-N arachidonic acid ethanolamide Natural products CCCCCC=CCC=CCC=CCC=CCCCC(=O)NCCO LGEQQWMQCRIYKG-UHFFFAOYSA-N 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 230000001593 cAMP accumulation Effects 0.000 description 1
- 239000003554 cannabinoid 1 receptor agonist Substances 0.000 description 1
- 239000003555 cannabinoid 1 receptor antagonist Substances 0.000 description 1
- 239000003536 cannabinoid receptor antagonist Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 235000005607 chanvre indien Nutrition 0.000 description 1
- QODRGVWMWOLMTE-SAABIXHNSA-N chembl176198 Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)N[C@@H]2CC[C@@H](O)CC2)N=C1C1=CC=C(Cl)C=C1Cl QODRGVWMWOLMTE-SAABIXHNSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 150000001907 coumarones Chemical class 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 229940095074 cyclic amp Drugs 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- CYQFCXCEBYINGO-IAGOWNOFSA-N delta1-THC Chemical compound C1=C(C)CC[C@H]2C(C)(C)OC3=CC(CCCCC)=CC(O)=C3[C@@H]21 CYQFCXCEBYINGO-IAGOWNOFSA-N 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 238000010931 ester hydrolysis Methods 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000011491 glass wool Substances 0.000 description 1
- 230000002140 halogenating effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005567 liquid scintillation counting Methods 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- BGJXNYVUVCFFFF-UHFFFAOYSA-N n'-(4-bromophenyl)-2,4-dichlorobenzenecarboximidamide Chemical compound ClC1=CC(Cl)=CC=C1C(=N)NC1=CC=C(Br)C=C1 BGJXNYVUVCFFFF-UHFFFAOYSA-N 0.000 description 1
- DBNQIOANXZVWIP-UHFFFAOYSA-N n,n-dimethyl-1,1-bis[(2-methylpropan-2-yl)oxy]methanamine Chemical compound CC(C)(C)OC(N(C)C)OC(C)(C)C DBNQIOANXZVWIP-UHFFFAOYSA-N 0.000 description 1
- IVMOOXFELCCOMP-UHFFFAOYSA-N n-(1-adamantyl)-1-(4-chlorophenyl)-2-[4-chloro-2-(trifluoromethyl)phenyl]imidazole-4-carboxamide Chemical compound FC(F)(F)C1=CC(Cl)=CC=C1C1=NC(C(=O)NC23CC4CC(CC(C4)C2)C3)=CN1C1=CC=C(Cl)C=C1 IVMOOXFELCCOMP-UHFFFAOYSA-N 0.000 description 1
- SVSQPQKRRBNFOC-UHFFFAOYSA-N n-(3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NN2CC3CCCC3C2)N=C1C1=CC=C(Cl)C=C1Cl SVSQPQKRRBNFOC-UHFFFAOYSA-N 0.000 description 1
- GEUFMHWPIXFMJY-UHFFFAOYSA-N n-(3,3a,4,5,6,6a-hexahydro-1h-cyclopenta[c]pyrrol-2-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)imidazole-4-carboxamide Chemical compound C1=CC(Cl)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NN2CC3CCCC3C2)=C1 GEUFMHWPIXFMJY-UHFFFAOYSA-N 0.000 description 1
- HXLFSLVUWNBRDT-UHFFFAOYSA-N n-(azepan-1-yl)-1-(4-bromophenyl)-2-(2,4-dichlorophenyl)imidazole-4-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1C1=NC(C(=O)NN2CCCCCC2)=CN1C1=CC=C(Br)C=C1 HXLFSLVUWNBRDT-UHFFFAOYSA-N 0.000 description 1
- SMEFNROEYLLVDY-UHFFFAOYSA-N n-(azepan-1-yl)-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methylimidazole-4-carboxamide Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)NN2CCCCCC2)N=C1C1=CC=C(Cl)C=C1Cl SMEFNROEYLLVDY-UHFFFAOYSA-N 0.000 description 1
- UNINKSRMOUERSC-UHFFFAOYSA-N n-(azepan-1-yl)-1-(4-chloropyridin-2-yl)-2-(2,4-dichlorophenyl)-5-ethylimidazole-4-carboxamide Chemical compound C=1C(Cl)=CC=NC=1N1C(CC)=C(C(=O)NN2CCCCCC2)N=C1C1=CC=C(Cl)C=C1Cl UNINKSRMOUERSC-UHFFFAOYSA-N 0.000 description 1
- GUNCGMZWTDRAJL-UHFFFAOYSA-N n-(azepan-1-yl)-1-(4-chloropyridin-2-yl)-2-(2,4-dichlorophenyl)-5-methylimidazole-4-carboxamide Chemical compound C=1C(Cl)=CC=NC=1N1C(C)=C(C(=O)NN2CCCCCC2)N=C1C1=CC=C(Cl)C=C1Cl GUNCGMZWTDRAJL-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- RYQNMPVOTHTFIF-UHFFFAOYSA-N n-benzyl-1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-n-methylimidazole-4-carboxamide Chemical compound C=1N(C=2C=CC(Cl)=CC=2)C(C=2C(=CC(Cl)=CC=2)Cl)=NC=1C(=O)N(C)CC1=CC=CC=C1 RYQNMPVOTHTFIF-UHFFFAOYSA-N 0.000 description 1
- NMJMVGDVVZUPOP-UHFFFAOYSA-N n-cyclohexyl-2-(1,5-dimethylpyrrol-2-yl)-5-ethyl-1-phenylimidazole-4-carboxamide Chemical compound C=1C=CC=CC=1N1C(CC)=C(C(=O)NC2CCCCC2)N=C1C1=CC=C(C)N1C NMJMVGDVVZUPOP-UHFFFAOYSA-N 0.000 description 1
- VSXOYDKSPXUUIJ-UHFFFAOYSA-N n-cyclohexyl-2-(2,4-dichlorophenyl)-1-(2,5-difluorophenyl)-5-ethylimidazole-4-carboxamide Chemical compound C=1C(F)=CC=C(F)C=1N1C(CC)=C(C(=O)NC2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl VSXOYDKSPXUUIJ-UHFFFAOYSA-N 0.000 description 1
- WUDKZQUCAOXVAT-UHFFFAOYSA-N n-cyclohexyl-2-(2,4-dichlorophenyl)-1-(2,5-difluorophenyl)-5-methylimidazole-4-carboxamide Chemical compound C=1C(F)=CC=C(F)C=1N1C(C)=C(C(=O)NC2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl WUDKZQUCAOXVAT-UHFFFAOYSA-N 0.000 description 1
- USKQSLWBDDIJSQ-UHFFFAOYSA-N n-cyclohexyl-2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)-5-methylimidazole-4-carboxamide Chemical compound C=1C=C(F)C=CC=1N1C(C)=C(C(=O)NC2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl USKQSLWBDDIJSQ-UHFFFAOYSA-N 0.000 description 1
- ZMRMCCQCBIVGDN-UHFFFAOYSA-N n-cyclohexyl-2-(2,4-dichlorophenyl)-1-(4-fluorophenyl)imidazole-4-carboxamide Chemical compound C1=CC(F)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NC2CCCCC2)=C1 ZMRMCCQCBIVGDN-UHFFFAOYSA-N 0.000 description 1
- XJWCYWLSWSGANR-UHFFFAOYSA-N n-cyclohexyl-2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)-5-methylimidazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NC2CCCCC2)=C1C XJWCYWLSWSGANR-UHFFFAOYSA-N 0.000 description 1
- TWRSTCDKXCLFEK-UHFFFAOYSA-N n-cyclohexyl-2-(2,4-dichlorophenyl)-1-(4-methoxyphenyl)imidazole-4-carboxamide Chemical compound C1=CC(OC)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NC2CCCCC2)=C1 TWRSTCDKXCLFEK-UHFFFAOYSA-N 0.000 description 1
- ZJVOQGJSTHDEJL-UHFFFAOYSA-N n-cyclohexyl-2-(2,4-dichlorophenyl)-1-[4-(trifluoromethyl)phenyl]imidazole-4-carboxamide Chemical compound C1=CC(C(F)(F)F)=CC=C1N1C(C=2C(=CC(Cl)=CC=2)Cl)=NC(C(=O)NC2CCCCC2)=C1 ZJVOQGJSTHDEJL-UHFFFAOYSA-N 0.000 description 1
- SBNWHIPARXVTSU-UHFFFAOYSA-N n-cyclohexyl-2-(2,4-dichlorophenyl)-1-pyridin-3-ylimidazole-4-carboxamide Chemical compound ClC1=CC(Cl)=CC=C1C1=NC(C(=O)NC2CCCCC2)=CN1C1=CC=CN=C1 SBNWHIPARXVTSU-UHFFFAOYSA-N 0.000 description 1
- HTHSZSOQRAXEAS-UHFFFAOYSA-N n-cyclohexyl-2-(2,4-dichlorophenyl)-5-methyl-1-[4-(trifluoromethyl)phenyl]imidazole-4-carboxamide Chemical compound C=1C=C(C(F)(F)F)C=CC=1N1C(C)=C(C(=O)NC2CCCCC2)N=C1C1=CC=C(Cl)C=C1Cl HTHSZSOQRAXEAS-UHFFFAOYSA-N 0.000 description 1
- VPVSRBWIFNSDMF-UHFFFAOYSA-N n-cyclohexyl-2-(2,5-dichlorophenyl)-5-ethyl-1-phenylimidazole-4-carboxamide Chemical compound C=1C=CC=CC=1N1C(CC)=C(C(=O)NC2CCCCC2)N=C1C1=CC(Cl)=CC=C1Cl VPVSRBWIFNSDMF-UHFFFAOYSA-N 0.000 description 1
- FBFGYIWCXJGEAG-UHFFFAOYSA-N n-cyclohexyl-2-(2,5-dichlorophenyl)-5-methyl-1-phenylimidazole-4-carboxamide Chemical compound C=1C=CC=CC=1N1C(C)=C(C(=O)NC2CCCCC2)N=C1C1=CC(Cl)=CC=C1Cl FBFGYIWCXJGEAG-UHFFFAOYSA-N 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 238000010647 peptide synthesis reaction Methods 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- IVSBKGWMJJCQHO-UHFFFAOYSA-N tert-butyl 1-(4-chlorophenyl)-2-(2,4-dichlorophenyl)-5-methylimidazole-4-carboxylate Chemical compound C=1C=C(Cl)C=CC=1N1C(C)=C(C(=O)OC(C)(C)C)N=C1C1=CC=C(Cl)C=C1Cl IVSBKGWMJJCQHO-UHFFFAOYSA-N 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/22—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with hetero atoms directly attached to ring nitrogen atoms
- C07D295/28—Nitrogen atoms
- C07D295/30—Nitrogen atoms non-acylated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C257/00—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines
- C07C257/10—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines
- C07C257/18—Compounds containing carboxyl groups, the doubly-bound oxygen atom of a carboxyl group being replaced by a doubly-bound nitrogen atom, this nitrogen atom not being further bound to an oxygen atom, e.g. imino-ethers, amidines with replacement of the other oxygen atom of the carboxyl group by nitrogen atoms, e.g. amidines having carbon atoms of amidino groups bound to carbon atoms of six-membered aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Description
Prisutan izum odnosi se na skupinu novih derivata 1H-imidazola, na metode priprave tih spojeva i na farmaceutske pripravke koji kao aktivan sastojak sadrže jedan ili više takvih spojeva.
Derivati 1H-imidazola su jaki agonisti kanabinoid-CB1 receptora, parcijalni agonisti ili antagonisti korisni u liječenju psihijatrijskih i neuroloških poremećaja, kao i ostalih bolesti koje su vezane uz kanabinoidnu neurotransmisiju.
Kanabiniodi su prisutni u indijskoj konoplji Cannabis sativa i već se stoljećima upotrebljavaju kao medicinski agensi (Mechoulam, R. i Feigenbaum J.J. Prog. Med. Chem. 1987, 24, 159). Tek su u zadnjih desetak godina istraživanja na području kanabinoida otkrila važne informacije o kanabinoidnim receptorima i njihovim (endogenim) agonistima i antagonistima. Otkriće i kasnije kloniranje dva različita podtipa kanabinoidnih receptora (CB1 i CB2) potaknulo je na istraživanje novih antagonista kanabinoidnih receptora (Munro, S. i ostali, Nature 1993, 365, 61. Matsuda, L.A. i Bonner, T.I. Cannabinoid Receptors, Pertwee, R.G. 1995, 117, Academic Press, London). Nadalje, farmaceutske su kompanije postale zainteresirane za razvoj kanabinoidnih lijekova za liječenje bolesti koje su vezane uz poremećaje kanabinoidnog sustava (Consroe, P. Neurobiology of Disease 1998, 5, 534. Pop, E. Curr. Opin. In CPNS Investigational Drugs 1999, 1, 587. Greenberg, D.A. Drug News Perspect. 1999, 12, 458. Pertwee, R.G., Progress in Neurobiology 2001, 63, 569). Do sada je poznato nekoliko antagonista CB1 receptora. Sanofi iznosi njihove diarilpirazolne analoge kao selektivne antagoniste CB1 receptora. Reprezentativni primjer je SR-141716A (Dutta, A.K. i ostali, Med. Chem. Res. 1994, 5, 54. Lan, R. i ostali, J. Med. Chem. 1999, 42, 769. Nakamura-Palacios, E.M. i ostali, CNS Drug Rev. 1999, 5, 43). CP-272871 je derivat pirazola, kao i SR141716A, no slabiji i manje podtip-selektivan od SR141716A (Meschler, J.P. i ostali, Pharmacol. 2000, 60, 1315). Otkriveno je da su aminoalkilindoli antagonisti CB1 receptora. Reprezentativni primjer je lodopravadolin (AM-630), predstavljen 1995. AM-630 je srednje aktivan antagonist CB1 receptora, no ponekad se ponaša kao slabi parcijalni agonist (Hosohata, K. i ostali, Life Sc. 1997, 61, PL115). Istraživači iz Eli Lily opisuju aril-aroil supstituirane benzofurane kao selektivne antagoniste CB1 receptora (npr. LY-320135) (Felder, C.C. i ostali, J. Pharmacol. Exp. Ther. 1998, 284, 291). 3-alkil-5,5'-difenilimidazolidindioni opisani su kao ligandi kanabinoidnog receptora, za koje se navodi da su kanabinoidni antagonisti (Kanyonyo, M. i ostali, Biorg. Med. Chem. Lett. 1999, 9, 2233). Aventis Pharma polagala je pravo na diarilmetilenazetidinske analoge kao antagoniste CB1 receptora (Mignani, S. i ostali, patent FR 2783246, 2000; Chem. Abstr. 2000, 132, 236982). Sanofi-Synthelabo je polagao pravo na tricikličke pirazole kao CB1 antagoniste (Barth, F. i ostali, patent WO 0132663; Chem. Abstr. 2001, 134, 340504). Zanimljivo, opisano je da se mnogi antagonisti CB1 receptora ponašaju kao inverzni agonisti in vitro (Landsman, R.S. i ostali, Eur. J. Pharmacol. 1997, 334, R1). Pirazolni kanabinoidi opisani su kao parcijalni agonisti CB1 receptora pokazujući kanabimimetičke učinke in vivo (Wiley, J.L. i ostali, J. Pharmacol. Exp. Ther. 2001, 296, 1013). Poznat je određeni broj skupina agonista CB1 receptora kao što su, na primjer, klasični kanabinoidi (npr. Δ9-THC), neklasični kanabinoidi, aminoalkilindoli i eikosanoidi (npr. anandamid). Časopisi omogućuju precizan pregled područja istraživanja kanabinoida (Mechoulam, R. i ostali, Prog. Med. Chem. 1998, 35, 199. Lambert, D.M. Curr. Med. Chem. 1999, 6, 635. Mechoulam, R. i ostali, Eur. J. Pharmacol. 1998, 359, 1. Williamson, E.M. i Evans, F.J. Drugs 2000, 60, 1303. Pertwee, R.G. Addiction Biology 2000, 5, 37. Robson, P. Br. J. Psychiatry 2001, 178, 107. Pertwee, R.G. Prog. Neurobiol. 2001, 63, 569. Goya, P; Jagerovic, N. Exp. Opin. Ther. Patents 2000, 10, 1529. Pertwee, R.G. Gut 2001, 48, 859).
Sada je neočekivano otkriveno da su novi derivati 1H-imidazola formule (I), njihovi prolijekovi i soli, jaki agonisti, parcijalni agonisti ili antagonisti kanabinoidnih CB1 receptora
[image]
pri čemu
R predstavlja fenil, tienil, 2-piridinil, 3-piridinil, 4-piridinil, pirimidinil, pirazinil, piridazinil ili triazinil, čije skupine mogu biti supstituirane s 1, 2, 3 ili 4 supstituenata Y, koji mogu biti isti ili različiti, iz skupine C1-3-alkila ili alkoksi-skupine, hidroksi-skupine, halogena, trifluormetila, trifluormetiltio-skupine, trifluormetoksi-skupine, nitro-skupine, amino-skupine, mono- ili dialkilne (C1-2)-amino-skupine, mono- ili dialkilne (C1-2)-amido-skupine, (C1-3)-alkoksikarbonila, karboksila, cijano-skupine, karbamoila i acetila, ili R predstavlja naftil uz uvjet da kada je R 4-piridinil R4 predstavlja halogeni atom ili cijano-skupinu, karbamoil, formil, acetil, trifluoracetil, fluoracetil, propionil, sulfamoil, metansulfonil, metilsulfanil ili razgranatu ili nerazgranatu C1-4 alkilnu skupinu, čija C1-4 alkilna skupina može biti supstituirana s 1-3 atoma fluora ili bromom, klorom, jodom, cijano-skupinom ili hidroksi-skupinom,
R1predstavlja fenil ili piridinil, čije skupine mogu biti supstituirane s 1-4 supstituenata Y, koji mogu biti isti ili različiti, pri čemu Y ima ranije spomenuto značenje, ili R1 predstavlja pirimidinil, pirazinil, piridazinil ili triazinil, čije skupine mogu biti supstituirane s 1-2 supstituenta Y, koji mogu biti isti ili različiti ili R1 predstavlja peteročlani aromatski, heterociklični prsten koji sadrži jedan ili dva heteroatoma iz skupine (N, O, S), čiji heteroatomi mogu biti isti ili različiti, čiji peteročlani aromatski, heterociklički prsten može biti supstituiran s 1-2 supstituenta Y, koji mogu biti isti ili različiti ili R1 predstavlja naftil,
R2 predstavlja H, razgranati ili nerazgranati C1-8 alkil, C3-8 cikloalkil, C3-8 alkenil, C5-8 cikloalkenil čije skupine mogu sadržavati atom sumpora, kisika ili dušika,
R3 predstavlja razgranati ili nerazgranati C2-8 alkil, C1-8 alkoksi-skupinu, C5-8 cikloalkoksi-skupinu, C3-8 cikloalkil, C5-10 bicikloalkil, C6-10 tricikloalkil, C3-8 alkenil, C5-8 cikloalkenil, čije skupine mogu izborno sadržavati jedan ili više heteroatoma iz skupine (O, N, S) i čije skupine mogu biti supstituirane hidroksi-skupinom, 1-2 C1-3 alkilne skupine ili 1-3 atoma fluora, ili R3 predstavlja benzilnu ili fenetilnu skupinu čiji aromatski prsteni mogu biti supstituirani s 1-5 supstituenata Z, koji mogu biti isti ili različiti, iz skupine C1-3-alkila ili alkoksi-skupine, hidroksi-skupine, halogena, trifluormetila, trifluormetiltio-skupine, trifluormetoksi-skupine, nitro-skupine, amino-skupine, mono- ili dialkilne (C1-2)-amino-skupine, mono- ili dialkilne (C1-2)-amido-skupine, (C1-3)-alkilsulfonila, dimetil-sulfamido-skupine, C1-3-alkoksikarbonila, karboksila, trifluormetinilsulfonila, cijano-skupine, karbamoila, sulfamoila i acetila, ili R3 predstavlja fenilnu ili piridinilnu skupinu, čije su skupine supstituirane s 1-4 supstituenata Z, pri čemu je Z prethodno definiran,
ili R3 predstavlja piridinilnu skupinu, ili R3 predstavlja fenilnu skupinu, uz uvjet da R4 predstavlja halogeni atom ili cijano-skupinu, karbamoil, formil, acetil, trifluoracetil, fluoracetil, propionil, sulfamoil, metansulfonil, metilsulfanil ili C1-4 alkilnu skupinu, čija C1-4 alkilna skupina može biti supstituirana s 1-3 atoma fluora ili bromom, klorom, jodom, cijano-skupinom ili hidroksi-skupinom,
ili R3 predstavlja skupinu NR5R6 uz uvjet da R2 predstavlja atom vodika ili metilnu skupinu, pri čemu
R5 i R6 su isti ili različiti i predstavljaju razgranati ili nerazgranati C1-4 alkil, ili R5 i R6 - zajedno s atomom dušika na koji su vezani - formiraju zasićenu ili nezasićenu, monocikličku ili bicikličku heterocikličku skupinu koja sadrži 4 do 10 atoma u prstenu čija heterociklička skupina sadrži jedan ili dva heteroatoma iz skupine (N, O, S), čiji heteroatomi mogu biti isti ili različiti, čija heterociklička skupina može biti supstituirana C1-3 alkilnom skupinom ili hidroksi-skupinom, ili R2 i R3 - zajedno s atomom dušika na koji su vezani – formiraju zasićenu ili nezasićenu heterocikličku skupinu koja sadrži 4 do 10 atoma u prstenu čija heterociklička skupina sadrži jedan ili dva heteroatoma iz skupine (N, O, S), čiji heteroatomi mogu biti isti ili različiti, čija heterociklička skupina može biti supstituirana C1-3 alkilnom skupinom ili hidroksi-skupinom,
R4 predstavlja atom vodika ili halogena ili cijano-skupinu, karbamoil, formil, acetil, trifluoracetil, fluoracetil, propionil, sulfamoil, metansulfonil, metilsulfanil ili razgranatu ili nerazgranatu C1-4 alkilnu skupinu, čija C1-4 alkilna skupina može biti supstituirana s 1-3 atoma fluora ili bromom, klorom, jodom, cijano-skupinom ili hidroksi-skupinom.
Zbog jake CB1 agonističke, parcijalne agonističke ili antagonističke aktivnosti, spojevi prema izumu su prikladni za upotrebu u liječenju psihijatrijskih poremećaja, kao što su psihoza, tjeskoba, depresija, pomanjkanja pozornosti, poremećaji pamćenja, kognitivni poremećaji, poremećaji prehrane, pretilost, ovisnost, ovisnost o lijekovima i neuroloških poremećaja, kao što su neurodegenerativni poremećaji, demencija, distonija, mišićni spazam, tremor, epilepsija, multipla skleroza, traumatska ozljeda mozga, moždani udar, Parkinsonova bolest, Alzheimerova bolest, epilepsija, Huntingtonova bolest, Touretteov sindrom, cerebralna ishemija, cerebralna apopleksija, kraniocerebralna trauma, moždani udar, ozljeda leđne moždine, neuroupalni poremećaji, plaque-skleroza, virusni encefalitis, poremećaji vezani uz demijelinizaciju, kao i u liječenju poremećaja boli, uključujući neuropatične poremećaje boli, te ostalih bolesti koje obuhvaćaju kanabinoidnu neurotransmisiju, uključujući liječenje septičkog šoka, glaukoma, karcinoma, dijabetesa, povraćanja, mučnine, astme, respiratornih bolesti, gastrointestinalnih poremećaja, želučanih čireva, proljeva i kardiovaskularnih poremećaja.
Afinitet spojeva izuma za kanabinoidne receptore CB1 određen je upotrebom membranskih preparata jajnih stanica kineskih hrčaka (CHO) u koje je stabilno transfektiran humani kanabinoidni receptor CB1 zajedno s radioligandom [3H]CP-55,940. Nakon inkubacije svježe pripravljenog preparata stanične membrane s [3H]-ligandom, sa ili bez dodatka spojeva izuma, odvajanje vezanog i slobodnog liganda izvedeno je filtracijom preko filtera od staklene vune. Radioaktivnost na filteru izmjerena je tekućinskim scintilacijskim brojanjem.
Kanabinoidna CB1 antagonistička aktivnost spojeva izuma određena je funkcionalnim istraživanjima upotrebom CHO stanica u kojima su humani kanabinoidni CB1 receptori stabilno eksprimirani. Adenilil-ciklaza stimulirana je upotrebom forskolina, te je izmjerena kvantitativnim određivanjem količine nakupljenog cikličkog AMP. Popratna aktivacija CB1 receptora agonistima CB1 receptora (npr. CP-55,940 ili (R)-WIN-55,212-2) može smanjiti nakupljanje cAMP koje je potaknuto forskolinom načinom ovisnim o koncentraciji. Odgovor kojim posreduje CB1 receptor može biti antagoniziran antagonistima CB1 receptora kao što su spojevi izuma.
Kanabinoidna agonistička ili parcijalno agonistička aktivnost spojeva izuma može se odrediti prema objavljenim metodama, kao što je određivanje kanabimimičkih učinaka in vivo (Wiley, J.L i ostali, J. Pharmacol. Exp. Ther. 2001, 296, 1013).
Izum se odnosi na racemate, smjese dijastereomera i pojedinačne stereoizomera spojeva formule (I).
Spojevi izuma mogu se dobiti u oblicima prikladnim za primjenu pomoću uobičajenih postupaka upotrebom pomoćnih tvari i/ili tekućih ili krutih nosača.
Prikladni sintetski putovi spojeva izuma su slijedeći:
Sintetski put A
Korak 1: esterska hidroliza spoja formule (II), pri čemu R7 predstavlja razgranatu ili nerazgranatu alkilnu skupinu (C1-4) ili benzilnu skupinu
[image]
Ovom reakcijom nastaje spoj formule (III)
[image]
pri čemu R, R1 i R4 imaju značenja jednaka ranije opisanim.
Međuprodukti formule (II), pri čemu R7 predstavlja razgranatu ili nerazgranatu alkilnu skupinu (C1-4) ili benzilnu skupinu mogu se dobiti poznatim metodama, na primjer:
a) I.K. Khanna i ostali, J. Med. Chem. 2000, 43, 3168-3185
b) N. Kudo i ostali, Chem. Pharm. Bull. 1999, 47, 857-868
c) K. Tsuji i ostali, Chem. Pharm. Bull. 1997, 45, 987-995
d) I.K. Khanna i ostali, J. Med. Chem. 1997, 40, 1634-1647
e) M. Guillemet i ostali, Tetrahedron Lett. 1995, 36, 547-548
Korak 2: Reakcija spoja formule (II) sa spojem formule R2R3NH, pri čemu R2 i R3 imaju značenja jednaka ranije opisanim, preko metoda aktivacije i spajanja, kao što je nastajanje aktivnog estera, ili u prisutnosti reagensa za spajanje, kao što su DCC, HBTU, BOP ili slični. Reakcijom nastaje željeni 1H-imidazolni derivat formule (I).
(Za dodatne informacije o metodama aktivacije i spajanja vidi: M. Bodanszky i A. Bodanszky: "The Practice of Peptide Syntheseis", Springer-Verlag, New York, 1994; ISBN: 0-387-57505-7).
Alternativno, spoj formule (III) reagira s agensom za halogeniranje, na primjer tionil-kloridom (SOCl2). Reakcijom nastaje odgovarajući karbonil-klorid (IV).
[image]
Reakcijom spoja formule (IV) sa spojem formule R2R3NH, pri čemu R2 i R3 imaju značenja jednaka ranije opisanim, nastaje 1H-imidazolni derivat formule (I). Ova se reakcija preferirano provodi u prisutnosti organske baze kao što je, na primjer, diizopropiletilamin (DIPEA) ili trietilamin.
Alternativno, spoj formule (II) reagira u amidacijskoj reakciji sa spojem formule R2R3NH, pri čemu R2 i R3 imaju značenja jednaka ranije opisanim, za dobivanje 1H-imidazolnog derivata formule (I).
Sintetski put B
Reakcija spoja formule (II), pri čemu R4 predstavlja vodik i pri čemu R, R1 i R7 imaju značenja jednaka ranije opisanim za spoj (II), sa spojem opće formule R4'-X, pri čemu X predstavlja izlaznu skupinu, a R4' predstavlja C1-4 alkilnu skupinu, čija alkilna skupina može biti supstituirana s 1-3 atoma fluora ili pri čemu R4' predstavlja cijano-, formilni, acetilni, trifluoracetilni, fluoracetilni, metilsulfanilni ili propionilni dio, ili pak atom halogena. Ova se reakcija provodi u prisutnosti jake, nenukleofilne baze kao što je litijev diizopropilamid (LDA), preferirano pod bezvodnim uvjetima u inertnom organskom otapalu, na primjer tetrahidrofuranu, te daje spoj formule (II)
[image]
pri čemu R, R1 i R7 imaju značenja jednaka ranije opisanim, a R4 predstavlja C1-4 alkilnu skupinu, čija alkilna skupina može biti supstituirana s 1-3 atoma fluora ili pri čemu R4 predstavlja cijano-skupinu, formilnu, acetilnu, trifluoracetilnu, fluoracetilnu, metilsulfanilnu ili propionilnu skupinu, ili pak atom halogena.
Spojevi opće formule (II), dobiveni sintetskim putem B, mogu se prevesti u spojeve opće formule (I) analogno postupcima opisanim u sintetskom putu A, koraku 1 puta A ili koraku 2 puta A (vidi prije).
Sintetski put C
Spojevi formule (II)
[image]
pri čemu R4 predstavlja razgranatu ili nerazgranatu C1-4 alkilnu skupinu, čija alkilna skupina može biti supstituirana s 1-3 supstituenta fluora i pri čemu R i R1 imaju ranije dana značenja, a R7 predstavlja razgranatu ili nerazgranatu alkilnu skupinu (C1-4) ili benzilnu skupinu, mogu se sintetizirati reakcijom spoja formule (V) ili njegovog tautomera
[image]
pri čemu R i R1 imaju ranije dana značenja, sa spojem formule (VI)
[image]
pri čemu R4 predstavlja razgranatu ili nerazgranatu C1-4 alkilnu skupinu, čija alkilna skupina može biti supstituirana s 1-3 atoma fluora, R8 predstavlja izlaznu skupinu, na primjer supstituent broma, a R7 predstavlja razgranatu ili nerazgranatu alkilnu skupinu (C1-4) ili benzilnu skupinu. Reakcija se preferirano provodi u organskom otapalu, na primjer 2-propanolu ili N-metil-2-pirolidinonu (NMP). Dodatak kiseline tijekom reakcije, kao što je trifluoroctena kiselina, može povećati nastajanje spoja formule (II).
(Za dodatne informacije o izlaznim skupinama vidi: M.B. Smith i J. March: "Advanced organic chemistry", str. 275, peto izdanje, (2001) John Wiley & Sons, New York, ISBN: 0-471-58589-0).
Spojevi opće formule (II), dobiveni sintetskim putem C, mogu se prevesti u spojeve opće formule (I) analogno postupcima opisanim u sintetskom putu A, koraku 1 puta A ili koraku 2 puta A (vidi prije).
Spojevi izuma formule (VI) mogu se dobiti poznatim metodama, na primjer: P. Seifert i ostali, Helv. Chim. Acta, 1950, 33, 725.
Sintetski put D
Reakcijom spoja formule (II)
[image]
pri čemu R4 predstavlja metilnu skupinu, R i R1 imaju ranije dana značenja, a R7 predstavlja razgranatu ili nerazgranatu alkilnu skupinu (C1-4) ili benzilnu skupinu, s regioselektivnim spojem za bromiranje, kao što je N-brom-sukcinimid (NBS), u organskom otapalu, kao što je CCl4, u prisutnosti slobodnog radikala kao inicijatora, kao što je dibenzoil-peroksid, nastaje spoj formule (VII)
[image]
pri čemu R, R1 i R7 imaju ranije dana značenja. Reakcijom spoja formule (VII) (analogno metodama opisanim u Mathews, W.B. i ostali, J. Label. Compds. Radiopharm., 1999, 42, 589) sa npr. KCl, KI, KF ili KCN nastaje spoj formule (VIII)
[image]
pri čemu R, R1 i R7 imaju ranije dana značenja, a Nu predstavlja klor, jod, fluor ili cijano-skupinu. Reakcija se preferirano provodi u prisutnosti slabe baze kao što je NaHCO3 ili u prisutnosti krunastog etera ili kriptanda. (Za dodatne informacije o krunastim eterima i kriptandima vidi: M.B. Smith i J. March: "Advanced organic chemistry", str. 105, peto izdanje, (2001) John Wiley & Sons, New York, ISBN: 0-471-58589-0).
Spojevi opće formule (VII) ili (VIII), dobiveni sintetskim putem D, mogu se prevesti u spojeve opće formule (I) analogno postupcima opisanim u sintetskom putu A, koraku 1 puta A ili koraku 2 puta A (vidi prije).
Primjer 1
Prvi dio: 1M otopini natrijevog bis(trimetilsilil)-amida u THF-u (70 mL) doda se kap po kap otopina 4-kloranilina (8,86 g, 69,5 mmola) u bezvodnom THF-u pod atmosferom dušika. Nakon što se smjesa miješa 20 minuta, doda joj se otopina 2,4-diklorbenzonitrila (12 g, 70 mmola) u THF-u. Dobivena smjesa miješa se preko noći, izlije u smjesu leda i vode (400 mL) i ekstrahira diklormetanom, zatim se osuši nad Na2SO4 i koncentrira in vacuo da se postigne dobivanje žutog ulja (15,7 g). Kristalizacija iz smjese diklormetan/heptan, te zatim ispiranje metil-t-butil-eterom daje N-(4-klorfenil)-2,4-diklorbenzenkarboksamidin (8,66 g, 42% iskorištenje) u obliku žute krutine. Točka taljenja (MP): 93-95°C.
Analogno je pripravljen:
N-(4-bromfenil)-2,4-diklorbenzenkarboksamidin. MP: 117-119°C.
Drugi dio: Smjesa N-(4-klorfenil)-2,4-diklorbenzenkarboksamidina (2,00 g, 6,68 mmola), etil-3-brom-2-oksopropanoata (2,65 g, 13,6 mmola) i NaHCO3 (1,12 g, 13,3 mmola) u 2-propanolu miješa se pri temperaturi refluksa 20 sati. Nakon hlađenja do sobne temperature, smjesa se koncentrira in vacuo, a ostatak se suspendira u dikormetanu, ispere vodom (3 x 50 mL) i vodenom otopinom natrijevog klorida (3 x 50 mL). Vodeni slojevi ekstrahiraju se diklormetanom. Spojeni organski slojevi osuše se nad Na2SO4 i koncentriraju in vacuo da se postigne dobivanje nepročišćenog smeđeg produkta (2,0 g). Produkt se zatim pročisti kolonskom kromatografijom (silikagel, heptan/EtOAc = 90/10 (v/v)) za dobivanje etilnog 1-(4-klorfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilata (0,759 g, 29% iskorištenje) u obliku žutog ulja koje se polagano skrućuje stajanjem. Točka taljenja: 150-152 °C; MS: 395 (MH+). 1H-NMR (400 MHz, CDCl3): δ� 7,91 (s, 1H), 7,49 (dd, J = 8 Hz, J = 2 Hz, 1H), 7,29-7,36 (m, 4H), 7,07 (dt, J = 8 Hz, J= 2 Hz, 2H), 4,44 (q, J = 7 Hz, 2H), 1,42 (t, J =7 Hz, 3H).
Treći dio: Etilni 1-(4-klorfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilat (0,810 g, 2,06 mmola) i LiOH (0,173 g, 7,20 mmola) otope se u smjesi H2O/THF (20 mL/20 mL) i miješaju se 16 sati pri 50 °C. Smjesa se koncentrira in vacuo da se postigne dobivanje 1-(4-klorfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilne kiseline. Zatim se doda tionil-klorid (60 mL) i smjesa se zagrijava pri temperaturi refluksa 1 sat, te se koncentrira in vacuo da se postigne dobivanje nepročišćenog 1-(4-klorfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karbonil-klorida.
Četvrti dio: Nepročišćeni 1-(4-klorfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karbonil-klorid (919 mg, ~2,39 mmola), 1-aminopiperidin (0,469 g, 4,69 mmola) i trietilamin (0,363 g, 3,59 mmola) otope se u diklormetanu i miješaju jedan sat pri sobnoj temperaturi. Smjesa se ispere zasićenom vodenom otopinom NaHCO3 (3 x 20 mL), osuši nad Na2SO4 i koncentrira in vacuo, te se zatim pročisti kolonskom kromatografijom (etil-acetat, silikagel) da se postigne dobivanje 1-(4-klorfenil)-2-(2,4-diklorfenil)-N-(piperidin-1-il)-1H-imidazol-4-karboksamida (356 mg, 26% iskorištenje (bazirano na etilnom 1-(4-klorfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilatu). Masena spektrometrija (MS): 449.
Analogno su pripravljeni:
2. 1-(4-klorfenil)-2-(2,4-diklorfenil)-N-(pirolidin-1-il)-1H-imidazol-4-karboksamid; MS: 435.
3. N-(t-butoksi)-1-(4-klorfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksamid; MS: 438.
4. 1-(4-klorfenil)-2-(2,4-diklorfenil)-N-fenil-1H-imidazol-4-karboksamid; MS: 442.
5. 1-(4-klorfenil)-N-cikloheksil-2-(2,4-diklorfenil)-1H-imidazol-4-karboksamid; MS: 448.
6. N-(benzil)-1-(4-klorfenil)-2-(2,4-diklorfenil)-N-metil-1H-imidazol-4-karboksamid; MS: 470.
7. 1-[1-(4-klorfenil)-2-(2,4-diklorfenil)-4-(1H-imidazolil)karbonil]-heksahidro-1H-azepin; MS: 448.
8. 2-(4-klorfenil)-1-(2,4-diklorfenil)-N-(piperidin-1-il)-1H-imidazol-4-karboksamid (pripravljen iz 2,4-dikloranilina i 4-klorbenzonitrila); MS: 449.
9. N-(t-butoksi)-2-(4-klorfenil)-1-(2,4-diklorfenil)-1H-imidazol-4-karboksamid (pripravljen iz 2,4-dikloranilina i 4-klorbenzonitrila); MS: 438.
Primjer 10
Prvi dio: Diizopropilamin (2,30 g, 22,8 mmola) se doda kap po kap u bezvodni THF (100 mL) u atmosferi dušika pri 0°C. Zatim se doda kap po kap n-BuLi (7,34 mL, 2,5 M otopina u heksanu, 18,4 mmola). Dobivena otopina se ohladi na -78°C. Zatim se doda kap po kap otopine etilnog 1-(4-klorfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilata (6,0 g, 15,2 mmola) u bezvodnom THF-u. Boja otopine se mijenja iz žute u grimiznosmeđu. Izmiješana smjesa se zagrije na -40°C, ohladi na -78°C i ostavi stajati 30 minuta. Doda se kap po kap metil-jodida (6,44 g, 45,4 mmola), dobivena otopina miješa se 30 minuta pri -78°C, a zatim se ostavi da postigne sobnu temperaturu. Reakcija se zaustavi vodenom otopinom NH4Cl, doda se dietil-eter, a organski sloj se osuši nad MgSO4, profiltrira i koncentrira in vacuo da se postigne dobivanje ulja (6,4 g). Ulje se pročisti kolonskom kromatografijom (toluen/EtOAc = 10/2 (v/v), silikagel) da se postigne dobivanje čistog etilnog 2-(4-klorfenil)-1-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karboksilata (5,3 g, 85% iskorištenje) u obliku žutog ulja.
Drugi dio: Etilni 2-(4-klorfenil)-1-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karboksilat (0,250 g, 0,61 mmola) i LiOH (0,052g, 2,17 mmola) otope se u smjesi H2O/THF (1:1 (v/v); 50 mL) i smjesa se miješa jedan sat pri 50°C. Smjesa se koncentrira da se postigne dobivanje nepročišćene 2-(4-klorfenil)-1-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karboksilne kiseline. U smjesu se doda SOCl2 (50 mL), a dobivena smjesa se zagrijava jedan sat pri temperaturi refluksa. Smjesa se koncentrira da se postigne dobivanje 2-(4-klorfenil)-1-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karbonil-klorida.
Treći dio: 2-(4-klorfenil)-1-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karbonil-klorid (1,5 g, 3,75 mmola), 1-aminopiperidin (0,725 g, 7,25 mmola) i trietilamin (0,549 g, 5,44 mmola) otope se u diklormetanu i miješaju jedan sat pri sobnoj temperaturi. Smjesa se ispere zasićenom vodenom otopinom NaHCO3, osuši nad Na2SO4 i koncentrira in vacuo, te se zatim pročisti kolonskom kromatografijom (heptan/etil-acetat = 1/1 (v/v), silikagel) da se postigne dobivanje 2-(4-klorfenil)-1-(2,4-diklorfenil)-5-metil-N-(piperidin-1-il)-1H-imidazol-4-karboksamida (0,220 g, 13% iskorištenje) u obliku bijele pjene. MS: 463.
Analogno su pripravljeni:
11. N-(t-butoksi)-2-(4-klorfenil)-1-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karboksamid: MS: 452.
12. 1-(4-klorfenil)-2-(2,4-diklorfenil)-5-metil-N-(piperidin-1-il)-1H-imidazol-4-karboksamid: MS: 463. Točka taljenja: 165-167oC.
13. N-(t-butoksi)-2-(2,4-diklorfenil)-1-(4-klorfenil)-5-metil-1H-imidazol-4-karboksamid: MS: 452.
14. N-(t-butoksi)-1-(4-klorfenil)-2-(2,4-diklorfenil)-5-etil-1H-imidazol-4-karboksamid: Amorfan. MS: 468.
15. 1-(4-klorfenil)-2-(2,4-diklorfenil)-5-etil-N-(piperidin-1-il)-1H-imidazol-4-karboksamid: MS: 477.
16. 1-(4-bromfenil)-N-(t-butoksi)-2-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karboksamid: Amorfan.
17. 1-(4-bromfenil)-2-(2,4-diklorfenil)-5-metil-N-(piperidin-1-il)-1H-imidazol-4-karboksamid: MP: > 204oC. TLC (silikagel, EtOAc) Rf = 0.3.
18. 1-(4-bromfenil)-N-(t-butoksi)-2-(2,4-diklorfenil)-5-etil-1H-imidazol-4-karboksamid: Amorfan. TLC (silikagel, CH2Cl2/aceton = 9/1 (v/v)) Rf = 0.45.
19. 1-(4-bromfenil)-2-(2,4-diklorfenil)-5-etil-N-(piperidin-1-il)-1H-imidazol-4-karboksamid: MP: > 140oC. TLC (silikagel, EtOAc) Rf = 0.4.
20. 1-(4-bromfenil)-N-cikloheksil-2-(2,4-diklorfenil)-5-etil-1H-imidazol-4-karboksamid: Točka taljenja > 135-140oC.
21. 1-(4-bromfenil)-2-(2,4-diklorfenil)-5-etil-N-(n-pentil)-1H-imidazol-4-karboksamid: Sirup. TLC (silikagel, CH2Cl2/aceton = 19/1 (v/v)) Rf = 0.4.
Primjer 22
Prvi dio: U promiješanu otopinu etilnog 1-(4-bromfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilata (6,10 g, 0,0139 mola) u THF-u (70 mL) doda se LiOH (0,67 g, 0,0278 mola), a zatim voda (70 mL). Dobivena smjesa miješa se 16 sati pri 50°C da se postigne dobivanje bistre otopine. Nakon hlađenja do sobne temperature, doda se HCl (1N otopina, 28 mL) da se postigne dobivanje uljanog taloga koji se potpuno skrućuje kontinuiranim miješanjem i dodatkom vode (70 mL). Talog se sakupi filtracijom, ispere vodom i osuši in vacuo da se postigne dobivanje 1-(4-bromfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilne kiseline (4,92 g, 86% iskorištenje). Točka taljenja: 138-142°C.
Drugi dio: U promiješanu suspenziju 1-(4-bromfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilne kiseline (1,23 g, 2,99 mmola) u suhom acetonitrilu (40 mL) jedan za drugim se dodaju diizopropiletilamin (DIPEA) (1,15 mL, 6,6 mmola), o-benzotriazol-1-il-N,N,N',N'-tetrametiluronijev heksafluorfosfat (HBTU) (1,36 g, 3,6 mmola) i 1-aminopiperidin (0,39 mL, 3,6 mmola). Nakon 16 sati miješanja, dobivena smjesa se koncentrira in vacuo. Ostatak se otopi u etil-acetatu, te se doda vodena otopina NaHCO3. Etil-acetatni sloj se sakupi, ispere vodom i vodenom otopinom natrijevog klorida, osuši nad Na2SO4, profiltrira i koncentrira in vacuo da se postigne dobivanje nepročišćene krutine. Krutina se zatim pročisti prekristalizacijom iz acetonitrila da se postigne dobivanje 1-(4-bromfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksamida (830 mg, 56% iskorištenje). Točka taljenja: 219-221 °C.
Analogno su pripravljeni:
23. N-(t-butoksi)-1-(4-bromfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksamid. Amorfan. TLC (silikagel, Et2O) Rf = 0.3.
24. 1-(4-bromfenil)-2-(2,4-diklorfenil)-N-(pirolidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: 238-240oC.
25. N-(azepan-1-il)-1-(4-bromfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksamid. Točka taljenja: 201-204oC.
26. 1-(4-klorfenil)-2-(2,4-diklorfenil)-N-(heksahidrociklopenta[c]pirol-2(1H)-il)-1H-imidazol-4-karboksamid. MS: 475.
27. 1-(4-klorfenil)-2-(2,4-diklorfenil)-N-(4-fluorbenzil)-1H-imidazol-4-karboksamid. MS: 474.
28. 1-(4-klorfenil)-2-(2-metoksi-4-klorfenil)-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: 220oC.
29. 1-(4-klorfenil)-N-cikloheksil-2-(2-metoksi-4-klorfenil)-1H-imidazol-4-karboksamid. Točka taljenja: 177-179oC.
30. 1-(4-klorfenil)-2-(2-fluor-4-klorfenil)-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: 217-218oC.
31. 2-(2,4-diklorfenil)-1-(4-fluorfenil)-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: 175-176oC.
32. N-cikloheksil-2-(2,4-diklorfenil)-1-(4-fluorfenil)-1H-imidazol-4-karboksamid. Točka taljenja: 184-185oC.
33. N-cikloheksil-2-(2-fluor-4-klorfenil)-1-(4-klorfenil)-1H-imidazol-4-karboksamid. Točka taljenja: 157-159oC.
34. 1-(4-klorfenil)-2-(2-metoksi-4-klorfenil)-N-(n-pentil)-1H-imidazol-4-karboksamid. Točka taljenja: 115oC.
35. 2-(2,4-diklorfenil)-1-(4-metoksifenil)-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: 178-179oC.
36. N-cikloheksil-2-(2,4-diklorfenil)-1-(4-metoksifenil)-1H-imidazol-4-karboksamid. Točka taljenja: 175-176oC.
37. 1-(4-klorfenil)-2-(2,4-diklorfenil)-N,N-dietil-1H-imidazol-4-karboksamid. Točka taljenja: 177-179oC.
38. 1-(4-klorfenil)-N-cikloheksil-2-(2-trifluormetil-4-klorfenil)-1H-imidazol-4-karboksamid. Točka taljenja: 172oC.
39. 1-(4-klorfenil)-N-(piperidin-1-il)-2-(2-trifluormetil-4-klorfenil)-1H-imidazol-4-karboksamid. Točka taljenja: 219oC.
40. N-(1-adamantil)-1-(4-klorfenil)-2-(2-trifluormetil-4-klorfenil)-1H-imidazol-4-karboksamid. Točka taljenja: 288 oC.
41. 1-(4-klorfenil)-N-(2,2,2-trifluoretil)-2-(2-trifluormetil-4-klorfenil)-1H-imidazol-4-karboksamid. Točka taljenja: 149oC.
42. 2-(2,4-diklorfenil)-1-(piridin-3-il)-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: 165-170oC.
43. N-cikloheksil-2-(2,4-diklorfenil)-1-(piridin-3-il)-1H-imidazol-4-karboksamid. Točka taljenja: 195oC.
44. 2-(2,4-diklorfenil)-1-(piridin-3-il)-N-(n-pentil)-1H-imidazol-4-karboksamid. Točka taljenja: 117oC.
Primjer 45
Prvi dio: 2,4-diklorbenzoil-klorid (40,0 g, 0,19 mola) otopi se u tetrahidrofuranu (1L). U dobivenu, promiješanu otopinu dodaju se jedan za drugim diizopropiletilamin (DIPEA), (73,4 mL, 2,2 molarni ekvivalent) i 4-(triflurmetil)fenilamin (30,7 g, 0,19 mola). Nakon jednog sata smjesa se koncentrira in vacuo da se postigne dobivanje ulja. Ulje kristalizira iz etanola da se postigne dobivanje čistog 2,4-di-klor-N-(4-(trifluormetil)fenil)benzamida (53,2 g, 83% iskorištenje). 1H-NMR (200 MHz, DMSO-d6): δ� 10,90 ( br s, 1H), 7,91 (br d, J = 8 Hz, 2H), 7,63-7,77 (m, 4H), 7,57 (dt, J = 8 Hz, J= 2 Hz, 1H).
Drugi dio: 2,4-diklor-N-(4-(trifluormetil)fenil)benzamid (19,0 g, 0,057 mola) otopi se u benzenu (150 mL) i doda se PCl5 (13,0 g, 1,1 molarni ekvivalent). Dobivena smjesa zagrijava se dva sata pri temperaturi refluksa, a zatim se ostavi hladiti do sobne tomperature i koncentrira in vacuo. Ostatak se otopi u bezvodnom THF-u, ohladi na 0°C i prenese u autoklav. Brzo se doda suvišak NH3 iz spremnika i smjesa se miješa 50 sati pri sobnoj temperaturi. Zatim se doda smjesa etil-acetata i vodene otopine NaHCO3. Etil-acetatni sloj se sakupi, osuši nad Na2SO4, profiltrira i koncentrira in vacuo. Dobiveno ulje se pročisti kolonskom kromatografijom (dietil-eter/petroleter = 1/1 (v/v), silikagel) da se postigne dobivanje čistog 2,4-diklor-N-(4-(trifluormetil)fenil)benzenkarboksamidina (16,9 g, 89% iskorištenje). Točka taljenja: 108-109°C.
Treći dio: 2,4-diklor-N-(4-(trifluormetil)fenil)benzenkarboksamidin (15,0 g, 0,045 mola) otopi se u 2-propanolu, te se jedan za drugim dodaju etil-3-brom-2-oksobutanoat (20,8 g, 2 molarni ekvivalent) i NaHCO3. Dobivena smjesa zagrijava se 40 sati pri temperaturi refluksa i ostavi hladiti do sobne temperature. 2-propanol se ukloni in vacuo, u ostatak se doda etil-acetat, a dobiveni organski sloj se ispere s NaHCO3 (5% vodena otopina). Etil-acetatni sloj se sakupi, osuši nad Na2SO4, profiltrira i koncentrira in vacuo. Dobiveno ulje se pročisti kolonskom kromatografijom (dietil-eter/petroleter = 1/3 (v/v), silikagel), a zatim prekristalizacijom iz cikloheksana da se postigne dobivanje etilnog 2-(2,4-diklorfenil)-5-metil-1-(4-(trifluormetil)fenil)-1H-imidazol-4-karboksilata (10,45 g, 52% iskorištenje) u obliku žute krutine. Točka taljenja: 160-162°C.
Četvrti dio: Dobiveni etilni 2-(2,4-diklorfenil)-5-metil-1-(4-(trifluormetil)fenil)-1H-imidazol-4-karboksilat prevede se u 2-(2,4-diklorfenil)-5-metil-1-(4-(trifluormetil)fenil)-1H-imidazol-4-karboksilnu kiselinu (točka taljenja 224-226°C), koja se zatim prevede u 2-(2,4-diklorfenil)-5-metil-N-(piperidin-1-il)-1-(4-(trifluormetil)fenil)-1H-imidazol-4-karboksamid (točka taljenja: 173-174°C) prema postupku opisanom u primjeru 22.
Analogno su pripravljeni:
46. 2-(2,4-diklorfenil)-N-(piperidin-1-il)-1-(4-(trifluormetil)fenil)-1H-imidazol-4-karboksamid. Točka taljenja: >200oC (raspad).
47. N-cikloheksil-2-(2,4-diklorfenil)-5-metil-1-(4-(trifluormetil)fenil)-1H-imidazol-4-karboksamid. Točka taljenja: 178-179oC.
48. N-cikloheksil-2-(2,4-diklorfenil)-1-(4-(trifluormetil)fenil)-1H-imidazol-4-karboksamid. Točka taljenja: 199-200oC.
Primjer 49
Prvi dio: N-(4-metoksifenil)-2,4-diklorbenzenkarboksamidin (15,0 g, 50,8 mmola) otopi se u 2-propanolu, te se jedan za drugim dodaju etil-3-brom-2-oksobutanoat (23,5 g, 2 molarna ekvivalenta) i NaHCO3 (8,5 g, 2 molarna ekvivalenta). Dobivena smjesa zagrijava se 40 sati pri temperaturi refluksa i ostavi hladiti do sobne temperature. 2-propanol se ukloni in vacuo, u ostatak se doda etil-acetat, a dobiveni organski sloj se ispere s NaHCO3 (5% vodena otopina). Etil-acetatni sloj se sakupi, osuši nad Na2SO4, profiltrira i koncentrira in vacuo. Dobiveno ulje se pročisti kolonskom kromatografijom (dietil-eter/petroleter = 1/3 (v/v), silikagel) da se postigne dobivanje etilnog 2-(2,4-diklorfenil)-5-metil-1-(4-metoksifenil)-1H-imidazol-4-karboksilata (8,61 g, 42% iskorištenje) u obliku krutine. 1H-NMR (200 MHz, CDCl3): δ�7,33 (d, J = 8 Hz, 1H), 7,27 (d, J = 2 Hz, 1H), 7,18 (dd, J = 8 Hz, J = 2 Hz, 1H), 7,03 (dt, J = 8 Hz, J = 2 Hz, 2H), 6,85 (dt, J = 8 Hz, J = 2 Hz, 2H), 4,42 (q, J = 7 Hz, 2H), 3,80 (s, 3H), 2,43 (s, 3H), 1,43 (t, J =7 Hz, 3H).
Drugi dio: U promiješanu otopinu etilnog 2-(2,4-diklorfenil)-5-metil-1-(4-metoksifenil)-1H-imidazol-4-karboksilata (8,00 g, 0,0198 mola) u THF-u (80 mL) doda se LiOH (0,59 g, 2 molarna ekvivalenta) i voda (80 mL). Dobivena smjesa miješa se 16 sati pri 80°C. Nakon hlađenja do sobne temperature doda se HCl (2N otopina, 12,3 mL) da se postigne dobivanje uljanog taloga. Nakon dodatka vode i ekstrakcije etil-acetatom, etil-acetatni sloj se sakupi, osuši nad Na2SO4, profiltrira i koncentrira in vacuo. Ostatak kristalizira iz diizopropil-etera, te se osuši da se postigne dobivanje 2-(2,4-diklorfenil)-5-metil-1-(4-metoksifenil)-1H-imidazol-4-karboksilne kiseline (4,04 g, 87% iskorištenje) u obliku svjetlosive krutine. Točka taljenja: 189-191°C.
Treći dio: U 2-(2,4-diklorfenil)-5-metil-1-(4-metoksifenil)-1H-imidazol-4-karboksilnu kiselinu (1,00 g, 2,65 mmola) u suhom acetonitrilu (25 mL) jedan za drugim se dodaju diizopropiletilamin (DIPEA) (1,02 mL, 2,2 molarna ekvivalenta) i o-benzotriazol-1-il-N,N,N',N'-tetrametiluronijev heksafluorfosfat (HBTU) (1,21 g, 1,2 molarna ekvivalenta), a dobivena otopina miješa se 15 minuta. Zatim se doda cikloheksilamin (0,36 mL, 1,2 molarna ekvivalenta). Nakon 50 sati miješanja dobivena smjesa se koncentrira in vacuo. Ostatak se otopi u diklormetanu i doda se vodena otopina NaHCO3. Diklormetanski sloj se sakupi, osuši nad Na2SO4, profiltrira i koncentrira in vacuo. Ostatak se zatim pročisti kolonskom kromatografijom (gradijent: diklormetan ⇒ diklormetan/metanol = 99/1 (v/v), silikagel) da se postigne dobivanje N-(1-cikloheksil)-2-(2,4-diklorfenil)-5-metil-1-(4-metoksifenil)-1H-imidazol-4-karboksamida (1,03 g, 85% iskorištenje). Točka taljenja: 160-161°C.
Analogno su pripravljeni:
50. 1-(4-klorfenil)-2-(2,4-diklorfenil)-N,N-5-trimetil-1H-imidazol-4-karboksamid. Točka taljenja: 101-104 oC.
51. 1-(4-klorpiridin-2-il)-2-(2,4-diklorfenil)-5-metil-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. MS: 464 (MH+).
52. 1-(4-klorpiridin-2-il)-2-(2,4-diklorfenil)-5-metil-N-(4-morfolinil)-1H-imidazol-4-karboksamid. MS: 466 (MH+).
53. N-(1-azepanil)-1-(4-klorpiridin-2-il)-2-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karboksamid. MS: 478 (MH+).
54. 1-(4-klorpiridin-2-il)-N-cikloheksil-2-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karboksamid. MS: 463.
55. 1-(4-klorpiridin-2-il)-2-(2,4-diklorfenil)-5-metil-N-(n-pentil)-1H-imidazol-4-karboksamid. MS: 451.
56. 1-(4-klorpiridin-2-il)-2-(2,4-diklorfenil)-N-(4-fluorbenzil)-5-metil-1H-imidazol-4-karboksamid. MS: 489. Točka taljenja: 123-126 oC.
57. 1-(4-klorfenil)-N-cikloheksil-5-metil-2-(2-trifluormetil-4-klorfenil)-1H-imidazol-4-karboksamid. Točka taljenja: 212oC.
58. 1-(4-klorfenil)-5-metil-N-(piperidin-1-il)-2-(2-trifluormetil-4-klorfenil)-1H-imidazol-4-karboksamid. Točka taljenja: 165oC.
59. 1-(4-klorfenil)-2-(2-metoksi-4-klorfenil)-5-metil-N-(n-pentil)-1H-imidazol-4-karboksamid. Točka taljenja: 131oC.
60. 1-(4-klorfenil)-2-(2-metoksi-4-klorfenil)-5-metil-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: > 256oC.
61. N-cikloheksil-1-(4-klorfenil)-2-(2-metoksi-4-klorfenil)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 201oC.
62. 2-(2,4-diklorfenil)-1-(4-fluorfenil)-5-metil-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: 223-224oC.
63. 2-(2,4-diklorfenil)-5-metil-1-(4-metoksifenil)-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: > 90oC (raspad).
64. N-cikloheksil-1-(4-fluorfenil)-2-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 229-230oC.
65. 1-(4-klorfenil)-5-metil-N-(n-pentil)-2-(2-trifluormetil-4-klorfenil)-1H-imidazol-4-karboksamid. Amorfan.
66. 1-(4-klorfenil)-2-(2-fluor-4-klorfenil)-5-metil-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: 195oC.
67. 1-(4-klorfenil)-2-(2-fluor-4-klorfenil)-5-metil-N-(n-pentil)-1H-imidazol-4-karboksamid. Točka taljenja: 115oC.
68. 1-(4-klorfenil)-N-(cikloheksil)-2-(2-fluor-4-klorfenil)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 188oC.
69. 1-(4-klorfenil)-N-(cikloheksil)-2-(1,5-dimetil-1H-pirol-2-il)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 188-189oC.
70. 1-(4-klorfenil)-2-(1,5-dimetil-1H-pirol-2-il)-5-metil-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: 208-210 oC.
71. 2-(2-klorfenil)-1-(3-fluorfenil)-5-metil-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: 236-238oC.
72. 2-(2-klorfenil)-1-(3-fluorfenil)-5-metil-N-(n-pentil)-1H-imidazol-4-karboksamid. Točka taljenja: 97-102oC.
73. 2-(2-klorfenil)-N-cikloheksil-1-(3-fluorfenil)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 180-182,5oC.
74. 2-(2-klorfenil)-1-(3-fluorfenil)-N-(2-(4-fluorfenil)etil)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 123,5-126oC.
75. 1-(4-klorpiridin-2-il)-2-(2,4-diklorfenil)-5-etil-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: 146oC.
76. 1-(4-klorpiridin-2-il)-2-(2,4-diklorfenil)-5-etil-N-(4-morfolinil)-1H-imidazol-4-karboksamid. Točka taljenja: 223oC.
77. N-(1-Azepanil)-1-(4-klorpiridin-2-il)-2-(2,4-diklorfenil)-5-etil-1H-imidazol-4-karboksamid. Točka taljenja: 177oC.
78. 1-(4-klorpiridin-2-il)-N-cikloheksil-2-(2,4-diklorfenil)-5-etil-1H-imidazol-4-karboksamid. Točka taljenja: 149oC.
79. 1-(4-klorpiridin-2-il)-2-(2,4-diklorfenil)-5-etil-N-(n-pentil)-1H-imidazol-4-karboksamid. Točka taljenja: Ulje.
80. 1-(4-klorpiridin-2-il)-2-(2,4-diklorfenil)-5-etil-N-(4-fluorfenilmetil)-1H-imidazol-4-karboksamid. Točka taljenja: amorfan.
81. 1-(4-klorfenil)-2-(2,4-diklorfenil)-N-(heksahidrociklopenta-[c]pirol-2(1H)-il)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 143-146oC.
82. 1-(4-klorfenil)-2-(2,4-diklorfenil)-5-metil-N-fenil-1H-imidazol-4-karboksamid. Točka taljenja: 91-95 oC.
83. 1-(4-klorfenil)-2-(2,4-diklorfenil)-5-metil-N-(tetrahidro-2H-piran-2-iloksi)-1H-imidazol-4-karboksamid. Točka taljenja: 128-133oC.
84. N-(exo-biciklo[2.2.1]hept-2-il)-1-(4-klorfenil)-2-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 194-195oC.
85. 1-(4-klorfenil)-2-(2,4-diklorfenil)-N-(2-fluoretil)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 128-133oC.
86. 1-(4-klorfenil)-2-(2,4-diklorfenil)-N-(trans-4-hidroksicikloheksil)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 160oC (raspad).
87. 1-{[1-(4-klorfenil)-2-(2,4-diklorfenil)-5-metil-1H-imidazol-4-il]karbonil}-4-hidroksipiperidin. Točka taljenja: Amorfan.
88. 1-{[1-(4-klorfenil)-2-(2,4-diklorfenil)-5-metil-1H-imidazol-4-il]karbonil}-1,2,3,4-tetrahidroizokvinolin. Točka taljenja: 143-146oC.
89. N-(endo-biciklo[2.2.1]hept-2-il)-1-(4-klorfenil)-2-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 194-195oC.
90. 1-(4-klorfenil)-2-(2,4-diklorfenil)-N-(4-fluorbenzil)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 165-166oC.
91. 1-(4-klorfenil)-2-(2,4-diklorfenil)-5-metil-N-(n-pentil)-1H-imidazol-4-karboksamid. Ulje.
92. N-(azepan-1-il)-1-(4-klorfenil)-2-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 147-149oC.
93. 1-(4-klorfenil)-2-(2,4-diklorfenil)-5-metil-N-(pirolidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: 205-206oC.
94. 1-(4-klorfenil)-2-(2,4-diklorfenil)-5-metil-N-(morfolin-4-il)-1H-imidazol-4-karboksamid. Točka taljenja: 225oC (raspad).
95. 2-(2,5-diklorfenil)-5-metil-1-fenil-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: 227oC.
96. N-cikloheksil-2-(2,5-diklorfenil)-5-metil-1-fenil-1H-imidazol-4-karboksamid. Točka taljenja: 236oC.
97. N-cikloheksil-2-(2,4-diklorfenil)-1-(2,5-difluorfenil)-5-etil-1H-imidazol-4-karboksamid. Točka taljenja: 144-146oC.
98. N-cikloheksil-2-(2,4-diklorfenil)-1-(2,5-difluorfenil)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 206-208oC.
99. N-cikloheksil-2-(1,5-dimetil-1H-pirol-2-il)-5-etil-1-fenil-1H-imidazol-4-karboksamid. Točka taljenja: 195-196 oC.
100. N-cikloheksil-2-(2,5-diklorfenil)-5-etil-1-fenil-1H-imidazol-4-karboksamid. Točka taljenja: 198-199 oC.
101. 2-(2,5-diklorfenil)-5-etil-1-fenil-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: 207-208oC.
102.1-(4-klorfenil)-5-metil-2-(3-metilpiridin-2-il)-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja: 211-213oC.
103.1-(4-klorfenil)-N-cikloheksil-5-metil-2-(3-metilpiridin-2-il)-1H-imidazol-4-karboksamid. Točka taljenja: 188-190oC.
104.1-(4-klorfenil)-2-(2,4-diklorfenil)-5-metil-N-(3-(trifluormetil)fenil)-1H-imidazol-4-karboksamid. Točka taljenja: 177oC.
105.1-(4-klorfenil)-2-(2,4-diklorfenil)-5-metil-N-(3-(trifluormetil)benzil)-1H-imidazol-4-karboksamid. Točka taljenja: 138-140oC.
106.1-(4-klorfenil)-2-(2,4-diklorfenil)-5-metil-N-(4-(trifluormetil)benzil)-1H-imidazol-4-karboksamid. Točka taljenja: 232oC.
107.1-(4-klorfenil)-N-ciklopentil-2-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 172oC.
108.1-(4-klorfenil)-N-cikloheptil-2-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karboksamid. Točka taljenja: 154-156oC.
Primjer 109
Prvi dio: Etilni 1-(4-bromfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilat prevede se u etilni 1-(4-bromfenil)-5-klor-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilat analogno objavljenom postupku (N. Kudo i ostali, Chem. Pharm. Bull. 1999, 47, 857-868) upotrebom suviška SO2Cl2 u diklormetanu, 50 sati pri temperaturi refluksa.
Drugi dio: Etilni 1-(4-bromfenil)-5-klor-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilat prevede se u 1-(4-bromfenil)-5-klor-2-(2,4-diklorfenil)-N-(piperidin-1-il)-1H-imidazol-4-karboksamid (točka taljenja: > 150 °C; Rf (silikagel, EtOAc) ~ 0,35) analogno postupku opisanom u primjeru 22. 1H-NMR (400 MHz, CDCl3): δ�7,85 (br s, 1H), 7,52 (dt, J = 8 Hz, J = 2 Hz, 2H), 7,26-7,36 (m, 3H), 7,01 (dt, J = 8 Hz, J = 2 Hz, 2H), 2,85-2,92 (m, 4H), 1,72-1,80 (m, 4H), 1,40-1,44 (m, 2H).
Primjer 110
Prvi dio: U promiješanu otopinu 1-(4-klorfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilne kiseline (18,38 g, 50,0 mmola) u toluenu (200 mL) u atmosferi dušika doda se N,N-dimetilformamidni di-tert-butil-acetal (50 mL) i dobivena smjesa zagrijava se 4 sata pri 80°C. Nakon hlađenja do sobne temperature reakcijska smjesa se koncentrira, te se doda dietil-eter. Dobivena otopina se dvaput ispere vodom, osuši nad MgSO4, profiltrira i koncentrira in vacuo. Ostatak kristalizira iz diizopropil-etera da se postigne dobivanje čistog tert-butilnog 1-(4-klorfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilata (10,35 g, 49% iskorištenje). Točka taljenja: 179-181 °C.
Drugi dio:
Litijev diizopropilamid (LDA) (5,25 mL 2M otopine u THF-u, 0,0105 mola) doda se kap po kap u ohlađenu otopinu (-70°C) tert-butilnog 1-(4-klorfenil)-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilata (4,24 g, 0,010 mola) u bezvodnom THF-u (80 mL) u atmosferi dušika i dobivena smjesa miješa se jedan sat. Zatim se, kap po kap, doda otopina p-toluensulfonil-cijanida (1,88 g, 0,011 mola) u bezvodnom THF-u, dobivena crvena otopina miješa se jedan sat pri -70°C i zatim se ostavi da postigne sobnu temperaturu. Zatim se doda dietil-eter, reakcija se zaustavi vodom, a reakcijska smjesa se profiltrira. Organski sloj se sakupi i ispere vodom, osuši nad MgSO4, profiltrira i koncentrira in vacuo da se postigne dobivanje ulja. Ulje se pročisti kolonskom kromatografijom (diklormetan, silikagel) da se postigne dobivanje 3,4 g tert-butilnog 1-(4-klorfenil)-5-cijano-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilata. Prekristalizacija iz dietil-etera daje kristalični tert-butilni 1-(4-klorfenil)-5-cijano-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilat (2,57 g, 57% iskorištenje). Točka taljenja 210-212 °C.
Analogno je pripravljen:
Tert-butilni 1-(4-klorfenil)-2-(2,4-diklorfenil)-5-metil-1H-imidazol-4-karboksilat. 1H-NMR (400 MHz, CDCl3): δ�7,38 (d, J = 8 Hz, 1H), 7,34 (dt, J = 8 Hz, J = 2 Hz, 2H), 7,27 (d, J = 2 Hz, 1H), 7,22 (dd, J = 8 Hz, J = 2 Hz, 1H), 7,03 (dt, J = 8 Hz, J = 2 Hz, 2H), 2,40 (s, 3H), 1,63 (s, 9H).
Treći dio:
U otopinu tert-butilnog 1-(4-klorfenil)-5-cijano-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilata (2,57 g, 5,73 mmola) u diklormetanu (40 mL) doda se trifluoroctena kiselina, dobivena otopina miješa se 20 sati pri sobnoj temperaturi i koncentrira in vacuo. Ostatak kristalizira iz diizopropil-etera da se postigne dobivanje čiste 1-(4-klorfenil)-5-cijano-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilne kiseline (1,95 g, 87% iskorištenje). Točka taljenja: 200-202°C (raspad).
Četvrti dio:
1-(4-klorfenil)-5-cijano-2-(2,4-diklorfenil)-1H-imidazol-4-karboksilna kiselina prevede se u 1-(4-klorfenil)-5-cijano-2-(2,4-diklorfenil)-N-(piperidin-1-il)-1H-imidazol-4-karboksamid u 60% iskorištenju, analogno postupku opisanom u primjeru 22, drugi dio. Točka taljenja: 231-233,5°C.
Analogno su pripravljeni:
111. 1-(4-klorfenil)-2-(2,4-diklorfenil)-5-jod-N-(piperidin-1-il)-1H-imidazol-4-karboksamid. Točka taljenja : 196-201oC.
112. 1-(4-klorfenil)-N-cikloheksil-2-(2,4-diklorfenil)-5-jod-1H-imidazol-4-karboksamid. Točka taljenja: 226-230oC.
1-(4-klorfenil)-5-cijano-N-cikloheksil-2-(2,4-diklorfenil)-1H-imidazol-4-karboksamid. Točka taljenja: 157-158oC.
Claims (10)
1. Spoj formule (I)
[image]
naznačen time, da
R predstavlja fenil, tienil, 2-piridinil, 3-piridinil, 4-piridinil, pirimidinil, pirazinil, piridazinil ili triazinil, čije skupine mogu biti supstituirane s 1, 2, 3 ili 4 supstituenata Y, koji mogu biti isti ili različiti, iz skupine C1-3-alkila ili alkoksi-skupine, hidroksi-skupine, halogena, trifluormetila, trifluormetiltio-skupine, trifluormetoksi-skupine, nitro-skupine, amino-skupine, mono- ili dialkilne (C1-2)-amino-skupine, mono- ili dialkilne (C1-2)-amido-skupine, (C1-3)-alkoksikarbonila, karboksila, cijano-skupine, karbamoila i acetila, ili R predstavlja naftil uz uvjet da kada je R 4-piridinil R4 predstavlja halogeni atom ili cijano-skupinu, karbamoil, formil, acetil, trifluoracetil, fluoracetil, propionil, sulfamoil, metansulfonil, metilsulfanil ili razgranatu ili nerazgranatu C1-4 alkilnu skupinu, čija C1-4 alkilna skupina može biti supstituirana s 1-3 atoma fluora ili bromom, klorom, jodom, cijano-skupinom ili hidroksi-skupinom,
R1predstavlja fenil ili piridinil, čije skupine mogu biti supstituirane s 1-4 supstituenata Y, koji mogu biti isti ili različiti, pri čemu Y ima ranije spomenuto značenje, ili R1 predstavlja pirimidinil, pirazinil, piridazinil ili triazinil, čije skupine mogu biti supstituirane s 1-2 supstituenta Y, koji mogu biti isti ili različiti ili R1 predstavlja peteročlani aromatski, heterociklični prsten koji sadrži jedan ili dva heteroatoma iz skupine (N, O, S), čiji heteroatomi mogu biti isti ili različiti, čiji peteročlani aromatski, heterociklički prsten može biti supstituiran s 1-2 supstituenta Y, koji mogu biti isti ili različiti ili R1 predstavlja naftil,
R2 predstavlja H, razgranati ili nerazgranati C1-8 alkil, C3-8 cikloalkil, C3-8 alkenil, C5-8 cikloalkenil čije skupine mogu sadržavati atom sumpora, kisika ili dušika,
R3 predstavlja razgranati ili nerazgranati C2-8 alkil, C1-8 alkoksi-skupinu, C5-8 cikloalkoksi-skupinu, C3-8 cikloalkil, C5-10 bicikloalkil, C6-10 tricikloalkil, C3-8 alkenil, C5-8 cikloalkenil, čije skupine mogu izborno sadržavati jedan ili više heteroatoma iz skupine (O, N, S) i čije skupine mogu biti supstituirane hidroksi-skupinom, 1-2 C1-3 alkilne skupine ili 1-3 atoma fluora, ili R3 predstavlja benzilnu ili fenetilnu skupinu čiji aromatski prsteni mogu biti supstituirani s 1-5 supstituenata Z, koji mogu biti isti ili različiti, iz skupine C1-3-alkila ili alkoksi-skupine, hidroksi-skupine, halogena, trifluormetila, trifluormetiltio-skupine, trifluormetoksi-skupine, nitro-skupine, amino-skupine, mono- ili dialkilne (C1-2)-amino-skupine, mono- ili dialkilne (C1-2)-amido-skupine, (C1-3)-alkilsulfonila, dimetil-sulfamido-skupine, C1-3-alkoksikarbonila, karboksila, trifluormetinilsu-lfonila, cijano-skupine, karbamoila, sulfamoila i acetila, ili R3 predstavlja fenilnu ili piridinilnu skupinu, čije su skupine supstituirane s 1-4 supstituenata Z, pri čemu je Z prethodno definiran,
ili R3 predstavlja piridinilnu skupinu, ili R3 predstavlja fenilnu skupinu, uz uvjet da R4 predstavlja halogeni atom ili cijano-skupinu, karbamoil, formil, acetil, trifluoracetil, fluoracetil, propionil, sulfamoil, metansulfonil, metilsulfanil ili C1-4 alkilnu skupinu, čija C1-4 alkilna skupina može biti supstituirana s 1-3 atoma fluora ili bromom, klorom, jodom, cijano-skupinom ili hidroksi-skupinom,
ili R3 predstavlja skupinu NR5R6 uz uvjet da R2 predstavlja atom vodika ili metilnu skupinu, pri čemu
R5 i R6 su isti ili različiti i predstavljaju razgranati ili nerazgranati C1-4 alkil, ili R5 i R6 - zajedno s atomom dušika na koji su vezani - formiraju zasićenu ili nezasićenu, monocikličku ili bicikličku heterocikličku skupinu koja sadrži 4 do 10 atoma u prstenu čija heterociklička skupina sadrži jedan ili dva heteroatoma iz skupine (N, O, S), čiji heteroatomi mogu biti isti ili različiti, čija heterociklička skupina može biti supstituirana C1-3 alkilnom skupinom ili hidroksi-skupinom, ili R2 i R3 - zajedno s atomom dušika na koji su vezani - formiraju zasićenu ili nezasićenu heterocikličku skupinu koja sadrži 4 do 10 atoma u prstenu čija heterociklička skupina sadrži jedan ili dva heteroatoma iz skupine (N, O, S), čiji heteroatomi mogu biti isti ili različiti, čija heterociklička skupina može biti supstituirana C1-3 alkilnom skupinom ili hidroksi-skupinom,
R4 predstavlja atom vodika ili halogena ili cijano-skupinu, karbamoil, formil, acetil, trifluoracetil, fluoracetil, propionil, sulfamoil, metansulfonil, metilsulfanil ili razgranatu ili nerazgranatu C1-4 alkilnu skupinu, čija C1-4 alkilna skupina može biti supstituirana s 1-3 atoma fluora ili bromom, klorom, jodom, cijano-skupinom ili hidroksi-skupinom,
i njegovi prolijekovi, stereoizomeri i soli.
2. Farmaceutski pripravci, naznačeni time, da kao aktivan sastojak sadrže farmakološki aktivnu količinu najmanje jednog spoja prema zahtjevu 1.
3. Metoda priprave farmaceutskog pripravka prema zahtjevu 2, naznačena time, da se spoj prema zahtjevu 1 dobiva u obliku prikladnom za primjenu.
4. Postupak za pripravu spojeva formule (I), naznačen time, da se spoj, pri čemu R, R1-R3 imaju značenja dana u zahtjevu 1, a R4 predstavlja vodik, atom halogena ili cijano-skupinu, karbamoilnu, formilnu, acetilnu, trifluoracetilnu, propionilnu, sulfamoilnu, metansulfonilnu, metilsulfanilnu ili C1-4 alkilnu skupinu, čija C1-4 alkilna skupina može biti supstituirana s 1-3 atoma fluora, pripravlja reakcijom spoja formule (II), (III) ili (IV) sa spojem formule R2R3NH.
5. Postupak za pripravu spojeva formule (II)
[image]
pri čemu R4 predstavlja C1-4 alkilnu skupinu, čija alkilna skupina može biti supstituirana s 1-3 supstituenta fluora, ili pri čemu R4 predstavlja atom halogena ili cijano-skupinu, formilnu, acetilnu, trifluoracetilnu, fluoroacetilnu, propionilnu ili metilsulfanilnu skupinu, naznačen time, da se spoj, pri čemu R i R1 imaju značenja dana u zahtjevu 1, a R7 predstavlja razgranatu ili nerazgranatu alkilnu skupinu (C1-4) ili benzilnu skupinu, pripravlja reakcijom spoja formule (II), pri čemu je R4 atom vodika, sa spojem formule R4'-X, pri čemu X predstavlja izlaznu skupinu, a R4' predstavlja C1-4 alkilnu skupinu, čija alkilna skupina može biti supstituirana s 1-3 supstituenta fluora ili pri čemu R4' predstavlja atom halogena ili cijano-skupinu, formilnu, acetilnu, trifluoracetilnu, fluoracetilnu, metilsulfanilnu ili propionilnu skupinu, u prisutnosti jake nenukleofilne baze.
6. Postupak za pripravu spoja formule (II)
[image]
pri čemu R4 predstavlja razgranatu ili nerazgranatu C1-4 alkilnu skupinu, čija C1-4 alkilna skupina može biti supstituirana s 1-3 supstituenta fluora, naznačen time, da se spoj, pri čemu R i R1 imaju značenja dana u zahtjevu 1, a R7 predstavlja razgranatu ili nerazgranatu alkilnu skupinu (C1-4) ili benzilnu skupinu, pripravlja reakcijom spoja formule (V) ili njegovog tautomera
[image]
pri čemu R i R1 imaju značenja dana u zahtjevu 1, sa spojem formule (VI)
[image]
pri čemu R4 predstavlja razgranatu ili nerazgranatu C1-4 alkilnu skupinu, čija alkilna skupina može biti supstituirana s 1-3 atoma fluora, R8 predstavlja takozvanu izlaznu skupinu, a R7 predstavlja razgranatu ili nerazgranatu alkilnu skupinu (C1-4) ili benzilnu skupinu.
7. Spojevi formule (IX)
[image]
naznačeni time, da R i R4 imaju značenja dana u zahtjevu 1 i pri čemu R1 predstavlja fenilnu ili piridinilnu skupinu, čije su skupine supstituirane s 1-4 supstituenata Y, koji mogu biti isti ili različiti, ili R1 predstavlja pirimidinilnu, pirazinilnu, piridazinilnu ili triazinilnu skupinu, čije su skupine supstituirane s 1-2 supstituenta Y, koji mogu biti isti ili različiti ili R1 predstavlja peteročlani aromatski heterociklički dio koji sadrži jedan ili dva heteroatoma iz skupine (O, N, S), čiji heteroatomi mogu biti isti ili različiti, čiji peteročlani aromatski heterociklički dio može biti supstituiran s 1-2 supstituenta Y, koji mogu biti isti ili različiti ili R1 predstavlja naftil, a R9 predstavlja hidroksi-skupinu, razgranatu ili nerazgranatu (C1-4) alkoksi-skupinu, benziloksi-skupinu ili supstituent klora.
8. Spojevi formule (X) i njihovi tautomeri
[image]
naznačeni time, da R predstavlja 4-klorfenilnu skupinu, 4-bromfenilnu skupinu ili 4-(trifluormetil)fenilnu skupinu.
9. Upotreba spoja prema zahtjevu 1, naznačena time, da se on koristi za pripravu farmaceutskog pripravka za liječenje poremećaja koji obuhvaćaju kanabinoidnu neurotransmisiju.
10. Upotreba prema zahtjevu 9, naznačena time, da su navedeni poremećaji psihijatrijski poremećaji, kao što su psihoza, tjeskoba, depresija, pomankanja pozornosti, poremećaji pamćenja, kognitivni poremećaji, poremećaji prehrane, pretilost, ovisnost, ovisnost o lijekovima i neurološki poremećaji, kao što su neurodegenerativni poremećaji, demencija, distonija, mišićni spazam, tremor, epilepsija, multipla skleroza, traumatska ozljeda mozga, moždani udar, Parkinsonova bolest, Alzheimerova bolest, epilepsija, Huntingtonova bolest, Touretteov sindrom, cerebralna ishemija, cerebralna apopleksija, kraniocerebralna trauma, moždani udar, ozljeda leđne moždine, neuroupalni poremećaji, plaque-skleroza, virusni encefalitis, poremećaji vezani uz demijelinizaciju, kao i za liječenje poremećaja boli, uključujući neuropatične poremećaje boli, te ostalih bolesti koje obuhvaćaju kanabinoidnu neurotransmisiju, uključujući liječenje septičkog šoka, glaukoma, karcinoma, dijabetesa, povraćanja, mučnine, astme, respiratornih bolesti, gastrointestinalnih poremećaja, želučanih čireva, proljeva i kardiovaskularnih poremećaja.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01203851 | 2001-09-21 | ||
PCT/EP2002/010434 WO2003027076A2 (en) | 2001-09-21 | 2002-09-17 | 1h-imidazole derivatives having cb1 agonistic, cb1 partial agonistic or cb1- antagonistic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20040185A2 true HRP20040185A2 (en) | 2004-08-31 |
Family
ID=8181044
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20040185A HRP20040185A2 (en) | 2001-09-21 | 2004-02-25 | 1h-imidazole derivatives having cb<sub>1</sub> agonistic, cb<sub>1</sub> partial agonistic or cb<sub>1</sub> antagonistic activity |
Country Status (26)
Country | Link |
---|---|
US (2) | US20040235854A1 (hr) |
EP (1) | EP1438296B1 (hr) |
JP (1) | JP4393869B2 (hr) |
KR (1) | KR100950431B1 (hr) |
CN (2) | CN101538244A (hr) |
AR (1) | AR036597A1 (hr) |
AT (1) | ATE415391T1 (hr) |
AU (1) | AU2002337106B2 (hr) |
BR (1) | BR0212481A (hr) |
CA (1) | CA2457444C (hr) |
DE (1) | DE60230054D1 (hr) |
DK (1) | DK1438296T3 (hr) |
ES (1) | ES2318045T3 (hr) |
HR (1) | HRP20040185A2 (hr) |
HU (1) | HUP0402150A3 (hr) |
IL (2) | IL160522A0 (hr) |
MX (1) | MXPA04002669A (hr) |
NO (1) | NO20041171L (hr) |
PL (1) | PL367998A1 (hr) |
PT (1) | PT1438296E (hr) |
RU (1) | RU2299200C2 (hr) |
SI (1) | SI1438296T1 (hr) |
TW (1) | TWI231757B (hr) |
UA (1) | UA77440C2 (hr) |
WO (1) | WO2003027076A2 (hr) |
ZA (1) | ZA200402188B (hr) |
Families Citing this family (113)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2002319627A1 (en) | 2001-07-20 | 2003-03-03 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US7109216B2 (en) | 2001-09-21 | 2006-09-19 | Solvay Pharmaceuticals B.V. | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
EP1430032A2 (en) * | 2001-09-24 | 2004-06-23 | Elan Pharmaceuticals, Inc. | Substituted amides for the treatment of neurological disorders |
HN2002000266A (es) | 2001-09-24 | 2003-11-16 | Bayer Corp | Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad. |
NZ534757A (en) | 2002-03-12 | 2006-07-28 | Merck & Co Inc | Substituted amides |
AU2003275242B2 (en) | 2002-09-27 | 2010-03-04 | Merck Sharp & Dohme Corp. | Substituted pyrimidines |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
US7294644B2 (en) | 2003-01-02 | 2007-11-13 | Hoffmann-La Roche Inc. | CB 1 receptor inverse agonists |
DE602004015408D1 (de) * | 2003-01-23 | 2008-09-11 | Us Genomics Inc | Verfahren zur analyse von polymer-populationen |
US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
PL377848A1 (pl) | 2003-02-07 | 2006-02-20 | Daiichi Pharmaceutical Co., Ltd. | Pochodne pirazoli |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
WO2004094407A1 (ja) * | 2003-04-21 | 2004-11-04 | Daiichi Pharmaceutical Co. Ltd. | 5員複素環誘導体 |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US20040224963A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the prevention and treatment of nicotine addiction in a mammal |
US20040224962A1 (en) * | 2003-05-09 | 2004-11-11 | Pfizer Inc | Pharmaceutical composition for the treatment of obesity or to facilitate or promote weight loss |
SE0301446D0 (sv) | 2003-05-16 | 2003-05-16 | Astrazeneca Ab | New Compounds |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
SE0301701D0 (sv) | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
SE0301698D0 (sv) | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
SE0301699D0 (sv) | 2003-06-10 | 2003-06-10 | Astrazeneca Ab | Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof |
US20040259887A1 (en) * | 2003-06-18 | 2004-12-23 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7276608B2 (en) | 2003-07-11 | 2007-10-02 | Bristol-Myers Squibb Company | Tetrahydroquinoline derivatives as cannabinoid receptor modulators |
US20050026983A1 (en) * | 2003-07-30 | 2005-02-03 | Pfizer Inc | Imidazole compounds and uses thereof |
US7326706B2 (en) | 2003-08-15 | 2008-02-05 | Bristol-Myers Squibb Company | Pyrazine modulators of cannabinoid receptors |
US20050239859A2 (en) * | 2003-09-03 | 2005-10-27 | Solvay Pharmaceuticals Gmbh | Novel medical uses of 4,5-dihydro-1h-pyrazole derivatives having cb1- antagonistic activity |
AU2004283903B2 (en) * | 2003-10-20 | 2010-12-02 | Solvay Pharmaceuticals B.V. | 1H-imidazole derivatives as cannabinoid receptor modulators |
TW200524908A (en) * | 2003-10-20 | 2005-08-01 | Solvay Pharm Bv | 1H-imidazole derivatives as cannabinoid receptor modulators |
BRPI0415851A (pt) * | 2003-10-24 | 2007-01-02 | Solvay Pharm Gmbh | utilizações médicas de compostos que apresentam atividade antagonìstica de cb1 e tratamento de combinação envolvendo os referidos compostos |
US20050143441A1 (en) * | 2003-10-27 | 2005-06-30 | Jochen Antel | Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity |
US20050124660A1 (en) * | 2003-10-27 | 2005-06-09 | Jochen Antel | Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds |
MXPA06004642A (es) | 2003-11-05 | 2006-06-27 | Hoffmann La Roche | Derivados de heteroaril como activadores de los receptores activados de proliferadores de peroxisoma (ppar). |
TW200522944A (en) | 2003-12-23 | 2005-07-16 | Lilly Co Eli | CB1 modulator compounds |
FR2866340B1 (fr) * | 2004-02-13 | 2006-11-24 | Sanofi Synthelabo | Derives d'oxazole, leur preparation et leur utilisation en therapeutique. |
US7173044B2 (en) * | 2004-02-19 | 2007-02-06 | Solvay Pharmaceuticals B.V. | Imidazoline derivatives having CB1-antagonistic activity |
ES2315851T3 (es) * | 2004-02-19 | 2009-04-01 | Solvay Pharmaceuticals B.V. | Derivados de imidazolina que tienen actividad antagonista cb1. |
AR047613A1 (es) * | 2004-02-19 | 2006-01-25 | Solvay Pharm Bv | Derivados de imidazolina que tienen actividad antagonista cb1 |
GB0404105D0 (en) * | 2004-02-24 | 2004-03-31 | Glaxo Group Ltd | Novel compounds |
CN1938023A (zh) * | 2004-03-08 | 2007-03-28 | 惠氏公司 | 离子通道调节剂 |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
CA2560417C (en) * | 2004-04-03 | 2011-04-19 | Astrazeneca Ab | 1,2-diarylimidazole-4-carboxamide derivatives |
CN1950361A (zh) | 2004-05-10 | 2007-04-18 | 霍夫曼-拉罗奇有限公司 | 用于治疗肥胖的吡咯或咪唑酰胺化合物 |
TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
US7524867B2 (en) | 2004-05-28 | 2009-04-28 | Solvay Pharmaceuticals, B.V. | Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity |
TW200608968A (en) * | 2004-05-28 | 2006-03-16 | Solvay Pharm Bv | Tetrasubstituted imidazole derivatives as cannabinoid cb1 receptor modulators with a high cb1/cb2 receptor subtype selectivity |
BRPI0510564A (pt) * | 2004-05-28 | 2007-11-20 | Solvay Pharm Bv | compostos e tautÈmeros, estereoisÈmeros, e sais farmacologicamente aceitáveis dos mesmos, composições farmacêuticas, método para preparar composições farmacêuticas, e, uso de um composto |
JP2008505965A (ja) | 2004-07-12 | 2008-02-28 | カディラ ヘルスケア リミティド | カンナビノイド受容体修飾因子としての三環式ピラゾール誘導体 |
US20060025448A1 (en) | 2004-07-22 | 2006-02-02 | Cadila Healthcare Limited | Hair growth stimulators |
FR2874012B1 (fr) * | 2004-08-09 | 2008-08-22 | Sanofi Synthelabo | Derives de pyrrole, leur preparation et leur utlisation en therapeutique |
MX2007004889A (es) | 2004-10-25 | 2007-09-11 | Solvay Pharm Gmbh | Composiciones farmaceuticas que comprenden antagonistas del receptor cannabinoide cb1 y activadores de canales de potasio para el tratamiento de la diabetes mellitus tipo i, la obesidad y trastornos relacionados. |
WO2006060190A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Imidazole derivatives |
WO2006060203A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Imidazole derivatives for the treatment of dementia and related disorders |
WO2006060202A2 (en) * | 2004-11-30 | 2006-06-08 | Bayer Pharmaceuticals Corporation | Imidazole derivatives for the treatment of psychiatric disorders |
NZ555320A (en) * | 2004-12-03 | 2010-11-26 | Schering Corp | Substituted piperazines as CB1 antagonists |
WO2006067428A2 (en) * | 2004-12-23 | 2006-06-29 | Astrazeneca Ab | 1, 2-diphenyl-imidazole derivatives and their use as cb1 receptor ligands |
EP2368881A1 (en) * | 2005-01-10 | 2011-09-28 | University of Connecticut | Heteropyrazole analogs acting on cannabinoid receptors |
US20110144128A1 (en) * | 2005-01-10 | 2011-06-16 | Exelixis, Inc. | Heterocyclic Carboxamide Compounds as Steroid Nuclear Receptors Ligands |
US8937184B2 (en) | 2005-02-16 | 2015-01-20 | Abbvie B.V. | 1H-imidazole derivatives as cannabinoid CB2 receptor modulators |
US7923465B2 (en) | 2005-06-02 | 2011-04-12 | Glenmark Pharmaceuticals S.A. | Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation |
PL1902034T3 (pl) | 2005-06-02 | 2011-09-30 | Glenmark Pharmaceuticals Sa | Nowe ligandy receptorów kanabinoidowych, kompozycja farmaceutyczna je zawierająca oraz proces ich wytwarzania |
NZ564759A (en) | 2005-06-30 | 2011-08-26 | Prosidion Ltd | GPCR agonists |
WO2007024744A2 (en) * | 2005-08-21 | 2007-03-01 | Exelixis, Inc. | Heterocyclic carboxamide compounds as steroid nuclear receptor ligands |
GB0518817D0 (en) * | 2005-09-15 | 2005-10-26 | Astrazeneca Ab | Therapeutic agents |
GB0518819D0 (en) * | 2005-09-15 | 2005-10-26 | Astrazeneca Ab | Therapeutic agents |
KR100694181B1 (ko) * | 2005-11-25 | 2007-03-12 | 연세대학교 산학협력단 | 근원세포 또는 근섬유로부터 신경세포 분화를 유도하는화합물, 이를 포함하는 약학적 조성물, 신경세포 분화를유도하는 방법 및 신경세포 분화를 유도하는 화합물을검색하는 스크리닝 방법 |
UY30048A1 (es) | 2005-12-23 | 2007-07-31 | Astrazeneca Ab | Derivados sustituidos de la n,2-(1h-benzimidazol-1-il) acetamida, composiciones farmacéuticas conteniéndolos, procesos de preparación y aplicaciones |
JP2009528266A (ja) * | 2006-01-18 | 2009-08-06 | シェーリング コーポレイション | カンナビノイド受容体修飾因子 |
TWI433839B (zh) | 2006-08-11 | 2014-04-11 | Neomed Inst | 新穎的苯并咪唑衍生物290 |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
AR064736A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr |
EA016507B1 (ru) | 2007-01-04 | 2012-05-30 | Прозидион Лимитед | Пиперидиновые агонисты gpcr |
PE20081659A1 (es) | 2007-01-04 | 2008-10-24 | Prosidion Ltd | Agonistas de gpcr |
ATE523507T1 (de) | 2007-01-04 | 2011-09-15 | Prosidion Ltd | Piperidin-gpcr-agonisten |
US20100197564A1 (en) * | 2007-04-19 | 2010-08-05 | Schering Corporation | Diaryl morpholines as cb1 modulators |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
US7879802B2 (en) | 2007-06-04 | 2011-02-01 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP2170846A2 (en) * | 2007-06-28 | 2010-04-07 | Intervet International BV | Substituted piperazines as cb1 antagonists |
EP2170847A2 (en) * | 2007-06-28 | 2010-04-07 | Intervet International BV | Substituted piperazines as cb1 antagonists |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
LT2963031T (lt) | 2007-11-30 | 2019-04-10 | Zynerba Pharmaceuticals, Inc. | Tetrahidrokanabinolio provaistai, provaistus apimančios tetrahidrokanabinolio kompozicijos ir jų panaudojimo būdai |
EP3239170B1 (en) | 2008-06-04 | 2019-03-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8822513B2 (en) | 2010-03-01 | 2014-09-02 | Gtx, Inc. | Compounds for treatment of cancer |
ES2927660T3 (es) | 2008-06-16 | 2022-11-10 | Univ Tennessee Res Found | Compuestos para el tratamiento del cáncer |
US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
EP3241839B1 (en) | 2008-07-16 | 2019-09-04 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010079241A1 (es) | 2009-01-12 | 2010-07-15 | Fundacion Hospital Nacional De Paraplejicos Para La Investigacion Y La Integracion | Uso de antagonistas y/o agonistas inversos de los receptores cb1 para la preparación de medicamentos que incrementen la excitabilidad de las motoneuronas |
US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
KR20120130777A (ko) | 2010-03-01 | 2012-12-03 | 유니버시티 오브 테네시 리서치 파운데이션 | 암 치료용 화합물 |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
EP2677869B1 (en) | 2011-02-25 | 2017-11-08 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
AU2013296470B2 (en) | 2012-08-02 | 2016-03-17 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
AU2014219020A1 (en) | 2013-02-22 | 2015-07-23 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
US9708367B2 (en) | 2013-03-15 | 2017-07-18 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase and their uses |
CA2905435A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
JP6606491B2 (ja) | 2013-06-05 | 2019-11-13 | シナジー ファーマシューティカルズ インコーポレイテッド | グアニル酸シクラーゼcの超高純度アゴニスト、その作成および使用方法 |
WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
CN106459004B (zh) | 2014-06-06 | 2020-09-15 | 研究三角协会 | 爱帕琳肽受体(apj)激动剂及其用途 |
AU2016366310C1 (en) | 2015-12-09 | 2021-09-09 | Research Triangle Institute | Improved apelin receptor (APJ) agonists and uses thereof |
JP7104690B2 (ja) | 2016-10-12 | 2022-07-21 | リサーチ トライアングル インスティテュート | 複素環式アペリン受容体(apj)アゴニスト及びそれらの使用 |
EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | ANTIDIABETIC HETEROCYCLIC COMPOUNDS |
CN111148734B (zh) * | 2017-08-28 | 2023-01-06 | 中国医学科学院药物研究所 | 吡咯-2-甲酰胺类化合物及其制备方法和用途 |
CN113166068A (zh) * | 2018-11-20 | 2021-07-23 | 上海科技大学 | MmpL3抑制剂、组合物及其用途 |
CN112558265B (zh) * | 2019-09-26 | 2022-04-19 | 张家港梓阳电子科技有限公司 | 一种用于气体准分子激光器镜头的锁定装置 |
CA3125847A1 (en) | 2020-07-27 | 2022-01-27 | Makscientific, Llc | Process for making biologically active compounds and intermediates thereof |
WO2024009283A1 (en) * | 2022-07-07 | 2024-01-11 | University Of Southern California | At2 antagonists for non-addictive pain relief |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DD140966A1 (de) * | 1978-12-28 | 1980-04-09 | Doerthe Creuzburg | Mittel zur regulierung des pflanzenwachstums |
US4813998A (en) * | 1986-02-27 | 1989-03-21 | Janssen Pharmaceutica N.V. | Herbicidal 1H-imidazole-5-carboxylic acid derivatives |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US5616601A (en) * | 1994-07-28 | 1997-04-01 | Gd Searle & Co | 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation |
FR2789079B3 (fr) * | 1999-02-01 | 2001-03-02 | Sanofi Synthelabo | Derive d'acide pyrazolecarboxylique, sa preparation, les compositions pharmaceutiques en contenant |
CO5170501A1 (es) * | 1999-04-14 | 2002-06-27 | Novartis Ag | AZOLES SUSTITUIDOS UTILES PARA EL TRATAMIENTO DE ENFERMEDADES MEDIADAS POR TNFa eIL-1 Y ENFERMEDADES DEL METABOLISMO OSEO |
US6492516B1 (en) | 1999-05-14 | 2002-12-10 | Merck & Co., Inc. | Compounds having cytokine inhibitory activity |
UA74367C2 (uk) | 2000-03-23 | 2005-12-15 | Сольве Фармас'Ютікалз Б.В. | ПОХІДНІ 4,5-ДИГІДРО-1Н-ПІРАЗОЛУ, ЩО ВИЯВЛЯЮТЬ АНТАГОНІСТИЧНУ АКТИВНІСТЬ ЩОДО СВ<sub>1</sub>, СПОСІБ ЇХ ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ ТА СПОСІБ ЇЇ ВИГОТОВЛЕННЯ, СПОСІБ ЛІКУВАННЯ ЗАХВОРЮВАНЬ (ВАРІАНТИ) |
ATE284872T1 (de) | 2001-03-22 | 2005-01-15 | Solvay Pharm Bv | 4,5-dihydro-1h-pyrazolderivate mit cb1- antagonistischer wirkung |
US7109216B2 (en) * | 2001-09-21 | 2006-09-19 | Solvay Pharmaceuticals B.V. | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity |
HN2002000266A (es) | 2001-09-24 | 2003-11-16 | Bayer Corp | Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad. |
AU2003209388A1 (en) | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
US7524867B2 (en) * | 2004-05-28 | 2009-04-28 | Solvay Pharmaceuticals, B.V. | Tetrasubstituted imidazole derivatives as cannabinoid CB1 receptor modulators with a high CB1/CB2 receptor subtype selectivity |
-
2002
- 2002-08-30 TW TW091119798A patent/TWI231757B/zh not_active IP Right Cessation
- 2002-09-17 CA CA2457444A patent/CA2457444C/en not_active Expired - Fee Related
- 2002-09-17 IL IL16052202A patent/IL160522A0/xx unknown
- 2002-09-17 WO PCT/EP2002/010434 patent/WO2003027076A2/en active IP Right Grant
- 2002-09-17 ES ES02772314T patent/ES2318045T3/es not_active Expired - Lifetime
- 2002-09-17 EP EP02772314A patent/EP1438296B1/en not_active Expired - Lifetime
- 2002-09-17 AT AT02772314T patent/ATE415391T1/de active
- 2002-09-17 SI SI200230794T patent/SI1438296T1/sl unknown
- 2002-09-17 MX MXPA04002669A patent/MXPA04002669A/es active IP Right Grant
- 2002-09-17 CN CNA2008101896834A patent/CN101538244A/zh active Pending
- 2002-09-17 RU RU2004111979/04A patent/RU2299200C2/ru not_active IP Right Cessation
- 2002-09-17 BR BR0212481-5A patent/BR0212481A/pt not_active IP Right Cessation
- 2002-09-17 PT PT02772314T patent/PT1438296E/pt unknown
- 2002-09-17 HU HU0402150A patent/HUP0402150A3/hu unknown
- 2002-09-17 KR KR1020047004084A patent/KR100950431B1/ko not_active IP Right Cessation
- 2002-09-17 CN CNA028183460A patent/CN1556703A/zh active Pending
- 2002-09-17 PL PL02367998A patent/PL367998A1/xx unknown
- 2002-09-17 AU AU2002337106A patent/AU2002337106B2/en not_active Ceased
- 2002-09-17 JP JP2003530667A patent/JP4393869B2/ja not_active Expired - Fee Related
- 2002-09-17 DE DE60230054T patent/DE60230054D1/de not_active Expired - Lifetime
- 2002-09-17 US US10/490,019 patent/US20040235854A1/en not_active Abandoned
- 2002-09-17 UA UA20040402980A patent/UA77440C2/uk unknown
- 2002-09-17 DK DK02772314T patent/DK1438296T3/da active
- 2002-09-18 AR ARP020103507A patent/AR036597A1/es unknown
-
2004
- 2004-02-23 IL IL160522A patent/IL160522A/en not_active IP Right Cessation
- 2004-02-25 HR HR20040185A patent/HRP20040185A2/hr not_active Application Discontinuation
- 2004-03-18 ZA ZA200402188A patent/ZA200402188B/en unknown
- 2004-03-19 NO NO20041171A patent/NO20041171L/no not_active Application Discontinuation
-
2008
- 2008-09-02 US US12/203,113 patent/US8729101B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20040185A2 (en) | 1h-imidazole derivatives having cb<sub>1</sub> agonistic, cb<sub>1</sub> partial agonistic or cb<sub>1</sub> antagonistic activity | |
US7109216B2 (en) | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1-antagonistic activity | |
AU2002337106A1 (en) | 1H-imidazole derivatives having CB1 agonistic, CB1 partial agonistic or CB1- antagonistic activity | |
CA2753061C (en) | Novel hetero pyrrole analogs acting on cannabinoid receptors | |
HRP20040085A2 (en) | Novel 4,5-dihydro-1h-pyrazole derivatives having cb-1 agonistic activity | |
JP2004500401A (ja) | Cb1−拮抗活性を有する4,5−ジヒドロ−1h−ピラゾール誘導体 | |
CZ20031795A3 (cs) | Fenylethenylové nebo fenylethynylové deriváty jako antagonisté glutamátového receptoru | |
AU2006328483A1 (en) | 4,5-dihydro- (1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | |
TW200934497A (en) | Heterocyclic derivatives | |
KR20130143141A (ko) | 피라졸리딘-3-온 유도체 | |
EP1675833B1 (en) | 1h-imidazole derivatives as cannabinoid receptor modulators | |
KR20100072037A (ko) | 칸나비노이드 cb₁수용체 효능제로서의 5-아릴-4,5-디하이드로-(1h)-피라졸 | |
US8410135B2 (en) | 4,5 dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | |
Lange et al. | 4, 5 Dihydro-(1H)-Pyrazole Derivatives as Cannabinoid CB1 Receptor Modulators | |
AU2008263915A1 (en) | 4,5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1 receptor modulators | |
TW200916442A (en) | 4, 5-dihydro-(1H)-pyrazole derivatives as cannabinoid CB1receptor modulators | |
TW200524908A (en) | 1H-imidazole derivatives as cannabinoid receptor modulators | |
TW200305411A (en) | Thiazole derivatives having CB-antagonistic, agonistic or partial agonistic activity |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20100906 Year of fee payment: 9 |
|
OBST | Application withdrawn |